

## CURRICULUM VITAE

**Michael Fredrick Vaezi, M.D., Ph.D.**

**Citizenship:** USA

**ABIM certification:** Gastroenterology- 2009-2019

### **EDUCATION/POSITIONS:**

Jan 2017-Current	Associate Chief and Clinical Director Division of Gastroenterology, Hepatology and Nutrition
2020-Current	Professional Development Steering Committee Department of Medicine
2021-Current	Committee for Appointments and Promotions Professional Development Steering Committee Department of Medicine
April-October 2016	Interim Chief, Division of Gastroenterology, Hepatology and Nutrition
2005-current	Professor of Medicine and Otolaryngology Clinical Director, Division Director, Center for Swallowing and Esophageal Disorders Director, Clinical Research Vanderbilt University Medical Center Nashville, Tennessee
2005	M.S. in Epidemiology Case Western Reserve University Cleveland, Ohio
1999-2005	Full Staff Associate Professor of Medicine Department of Gastroenterology and Hepatology Center for Swallowing and Esophageal Disorders Cleveland Clinic Foundation Cleveland, Ohio
1996-1999	Chief Fellow Gastroenterology Gastroenterology Fellowship

Cleveland Clinic Foundation  
Cleveland, Ohio

- 1992-1996 House-staff Physician in the Four-year Academic Internist Track program in the Department of Internal Medicine, University of Alabama Hospital, Birmingham, Alabama.
- 1988 - 1992 M.D.-University of Alabama School of Medicine, Birmingham, Alabama.
- 1983 - 1988 Ph.D.-Bio-Organic Chemistry; University of Alabama at Birmingham, Birmingham, Alabama, (degree received 1989).
- 1981 - 1983 B.S.-Birmingham-Southern College, Birmingham, Alabama, Chemistry, cum laude.

**LICENSURE:** State of Tennessee-2005-current  
State of Ohio – 1997-2009  
State of Alabama 1993

**NATIONAL  
COMMITTEES:**

ISDE (International Society for Diseases of the Esophagus-Board Member-2020-current.  
IWGCO (International Working Group for Classification of Oesophagitis)-Director-2019-current  
AGA- Nominating Committee; 2017-current  
AGA- Research Award Committee; 2017-current  
AGA- Chair, EGD Section; 2015-2017  
AGA- Vice Chair, EGD Section; 2013-2015  
AGA -Associate Chair EGD Section; 2008-2013  
AGA –Research Policy Committee; 2009-current  
ACG Research Grant Committee; 2009-2011  
ACG GI Pathophysiology Course Director; 2009-current  
Scientific Committee Member, ANMS; 2011-current  
Chair, ACG Publication Counsel; 2005-2009  
ASGE Educational Counsel 2005-2008  
Editorial Advisory Board, American Journal of Gastroenterology; 2015-now  
Editorial Board Clinical Gastroenterology and Hepatology; 2010-current  
Editorial Board American Journal of Gastroenterology; 2009-current  
Gastroenterology Fellowship Educational Committee member; 2003-present  
Editorial Advisory Board: Gastroenterology & Hepatology; 2007-current  
Section Editor of Current Gastroenterology Report; 2005-2008  
Contributor to Gastroenterology Selected Summaries; 2005-current  
AGA Abstract Review Committee; 2001-current  
AGA Program Chair; 2003-current  
Member of the GCRC research protocol review committee; 2003-2005

**HONORS:**

Outstanding Teacher Award; Division of Gastroenterology; 2018  
Grant W. Liddle Award- Vanderbilt House Staff Research Award;  
2016  
AGA Institute Council EGD Section Research Mentor Award; 2013  
Friends of Otolaryngology Award; ENT Department Vanderbilt;  
2013  
Communication Service Award; Dept Hearing and Speech; Vand.;  
2012  
American College of Gastroenterology/Astra Zeneca Senior Fellow  
Award  
Argus Society Award for excellence in teaching by a medicine resident,  
UAB; 1996.  
Two-time finalist in the Annual Trainee Research Symposium sponsored by  
the Department of Medicine, UAB; 1994 and 1995.  
Two-time finalist in the annual American College of Physicians Clinical  
Vignette Presentation, UAB; 1993 and 1996.  
Outstanding Graduate Student Award, UAB Department of Chemistry, 1986.  
First (1986) and second (1988) place winner of the Annual Sigma Xi  
Graduate Research Day Presentation Award.  
Dean's List at Birmingham-Southern College, 1982.  
Cum Laude Graduate  
Alpha Epsilon Delta (AED), Premedical Honor Society

**MEMBERSHIP:**

Member of the American Gastroenterological Association-1996-current  
Fellow member of the American College of Gastroenterology-1996-current  
Member of the American Society for Gastrointestinal Endoscopy-1996-2009

**PATENTS:**

- 1) Mucosal impedance for diagnosis of GERD and EoE
- 2) Synthesis and purification of conformationally restricted 6-s-cis and 6-s-trans retinoids and their potential in anticancer therapy.

**REVIEWER:**

Adhoc reviewer for NIDDK—2006-current  
Annals of Internal Medicine  
New England Journal of Medicine  
Gastroenterology  
Gut  
JAMA  
JAMA Otolaryngology  
American Journal of Physiology  
American Journal of Gastroenterology  
Clinical Gastroenterology and Hepatology  
Neurogastroenterology and Motility  
World Journal of Gastroenterology  
Alimentary Pharmacology & Therapeutics  
Diseases of the Esophagus  
Digestive Diseases and Science

Laryngoscope

**FUNDING**

**Investigator-Initiated Clinical Research:**

Effectiveness of physiologic testing in PPI non-responders  
R01DK092217 (Consultant)  
04/01/2017-03/31/2022  
Total Award: \$1,314,323

Dietary Carbohydrate Effects on GERD in Obese  
Veterans: Nutritional or Hormonal?  
CSR&D MERIT REVIEW AWARD FOR CLINICAL TRIALS  
Project #: CX001009 (Co-PI)  
04/01/15 – 03/31/20  
Total Award: \$764,000

“Mucosal impedance to diagnose GERD”  
2013-2020 Sandhill Scientific/Diversatek Healthcare  
Total Award: \$300,000

1K23DK059345-01A1- *“Reflux disease and throat symptoms and signs”*  
2002-2006  
\$444,000

ACG Career Development Award- *“The role of GERD in ENT signs and symptoms.”* – 2002-2004  
Total Award: \$100,000

“Sleep Position Reduces Acid Reflux and Decreases Extraesophageal  
Reflux Symptoms: A Non-randomized Prospective Study of the Amenity  
Health Medcline™ Sleep Assist Device”  
2014-2016 Amenity Health, Inc.  
Total Award: \$20,000

“ADHERE-pepsin study: use of dx-pH catheter and the role of salivary  
pepsin assay for patients with EERD”  
2011-2013 Takeda Pharmaceuticals, Inc.  
Total Award: \$95,000

“Prospective single blinded randomized controlled trial with sham  
comparing fluticasone and dexamethasone with or without esophageal  
dilation in patients with EoE”  
2010-2014 Takeda Pharmaceuticals, Inc.  
Total Award: \$84,000

“Can we predict who has GERD? Systematic evaluation of role of pH monitoring and its parameters in defining GERD”

2010-2011 Takeda Pharmaceuticals, Inc.

Total Award: \$35,000

“Effect of Aggressive Acid Suppression with Esomeprazole on Vocal Cord Granulomas: Randomized Placebo-Controlled Trial”

2008-2010 AstraZeneca Pharmaceuticals

Total Award: \$185,000

“Microscopic mucosal changes in GERD and extraesophageal reflux disease” 2007-2009 TAP Pharmaceuticals

Total Award: \$220,000

“Double Blind Placebo Controlled Study of Postnasal Drip and GERD Therapy”

2006-2008 TAP Pharmaceuticals

Total Award: \$250,000

“Dx-pH Probe: Validation and Clinical Assessment”

2007-2008 ResTech

Total Award: \$50,000

“Practice Pattern of ENT and GI Physicians in GERD Related Laryngitis”

2004-2006 TAP Pharmaceuticals

Total Award: \$30,000

“Dose Response of Acid and Duodenogastroesophageal (Bile) Reflux to Rabeprazole in Patients with Barrett’s Esophagus”

2002-2004 Janssen Pharmaceuticals

Total Award: \$100,000

“Role of Acid in Atypical GERD and Patients with Abnormal ENT Exam”

1999-2001 Tap Pharmaceuticals

Total Award: \$80,000

“Role of proton pump inhibition in atypical GERD”

1998-2000 AstraZeneca Pharmaceuticals

Total Award: \$30,000

“ENT manifestation of GERD and acid suppression”

1998-2000 Tap Pharmaceuticals

Total Award: \$40,000

### **Multi-Center Industry-Sponsored Clinical Trials:**

“A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis”

2018 – 2022 Allakos, Inc

Total Award: \$75,000

“A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Oral IW-378 Administered to Patients with Gastroesophageal Reflux Disease while Receiving Proton Pump Inhibitors”

2018 – 2021 Ironwood Pharmaceuticals, Inc

Total Award: \$50,000

“A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)”

2016 – 2020 Endostim

Total Award: \$400,000

“A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacodynamic Effect of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis”

2017 – 2019 Allakos, Inc

Total Award: \$75,000

“Oral: A Phase 3 Mutlicenter, Open-Label Continuation Study with Budesonide Oral Suspension (BOS) in Adolescent and Adult Subjects with Eosinophilic Esophagitis (SHP621-303)”

2017-2019 Shire Pharmaceuticals, Inc.

Total Award: \$50,000

“Oral budesonide suspension (OBS) in Adolescent and Adult Subjects (11 to 55 years of age, inclusive) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-Controlled Study (SHP621-301)”

2016-2018 Shire Pharmaceuticals, Inc.

Total Award: \$40,000

“A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients with Achalasia (C1701-201)”

2017-2018 Ironwood Pharmaceuticals, Inc.

Total Award: \$120,000

“A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients with Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors”

2015-2017 Ironwood Pharmaceuticals, Inc.

Total Award: \$15,000

“A Phase 2, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects with Eosinophilic Esophagitis”

2014-2016 Receptos Pharmaceuticals, Inc.

Total Award: \$20,962

**SOCIETY / ACADEMIC  
EDUCATIONAL  
ACTIVITIES  
(Selected examples)**

**2021:**

International Neurogastro Week-Feb 2021  
Mexican Association of Neurogastroenterology and Motility  
“Laryngitis and cough: GERD or hypersensitivity?”

AGA 2020 GERD/Barrett’s Consensus Conference-March 2021  
“New Innovation in GERD physiologic testing”

Federation of Neurogastroenterology and Motility-April 2021  
“GERD and mucosal integrity”

Digestive Disease Week (DDW)-May 2021  
Virtual.  
“Extraesophageal GERD-panel discussion”-Post Graduate Course”

**2020:**

**HELLO COVID**

Digestive Disease Week (DDW)-May 2020  
Virtual.  
“Difficult to treat GERD”-Post Graduate Course”  
“Extraesophageal GERD: When are they real?”

**2019:**

Annual Digestive Diseases of the Caribbean February 2019

“Refractory GERD” and “Extraesophageal Reflux Disease”  
San Juan, PR

10<sup>th</sup> Expert Strategies in Endoscopy; KU Medical Center/Mayo Clinic  
GI and Liver Disorders; March 2019  
“What is New in GERD Therapy?” and “Functional GI Symptoms”  
Kansas City, MO

Gastroenterology Grand Rounds-Northwestern Medicine; March 6  
“Mucosal Integrity Testing”  
Chicago, IL  
GALA Conference Dallas-March 2019  
“Impact of Bariatric Surgery on Esophageal Function and GERD”  
Dallas, TX

AGA Technology Summit-April 2019  
“What Criteria do Anti-Reflux Technologies Need to Achieve to Gain  
Adoption?”  
San Francisco, CA

Medicine Grand Rounds-UNC Carolina Health Care; April 6  
“Challenges in Diagnosis and Management of GERD”  
Charlotte, NC

Esophageal Sensory and Motor Function and Dysfunction-May 2019  
“Esophageal Function Testing”  
San Diego, CA

Digestive Disease Week (DDW)-May 2019  
San Diego, CA

Oral Presentations:

“Impact of iw-3718, a novel gastric-retentive bile acid sequestrant, on a  
spectrum of GERD symptoms in patients with persistent GERD receiving  
PPI’s – results from a double-blind, placebo-controlled study”

“Mucosal integrity testing: when and why?”

“BMI rather than symptoms is associated with altered esophageal MI in  
patients with refractory GERD”

“Medical management of refractory GERD”

Poster Presentations:

“Esophageal MI is unchanged in patients with functional heartburn and  
reflux hypersensitivity”

“MI predicts ability to discontinue PPI among PPI non-responders”

“Esophageal pathology is likely etiology of dysphagia regardless of cervical  
or substernal localization”

“Impact of chronic opioids on esophageal motility”



GALA Conference Dallas-June 2019  
“Impact of Bariatric Surgery on Esophageal Function and GERD”  
Fort Lauderdale, FL

Digital II Gastro Forum-June 2019  
“What’s new on GERD treatment?”  
“Extra esophageal reflux disease”  
Achalasia: How to diagnose and treat?”

ANMS annual Meeting-August 2019  
“Mucosal Impedance studies of the esophagus”  
Chicago, IL

5<sup>th</sup> Annual Florida Gastroenterological Association – September 2019  
“LPR: Reflux or Reflex?” and EoE: Diagnosis and Management”  
Orlando, FL

**2018:**

Medicine Grand Rounds-Vanderbilt University Medical Center-Jan 2018  
“Research Update in GERD”  
Nashville, TN

AGA Nominating Committee-Jan 27<sup>th</sup>, 2018  
Washington DC

Annual Minimally Invasive Surgery Symposium-March 2018  
“Work Up of GERD”  
“Gastroenterologist View of Anti-Reflux Surgery”  
“Endoscopic diagnosis and Management of Barrett’s esophagus”  
Las Vegas, NV

Medicine Grand Rounds; University of Virginia-April 2018  
“GERD and Extraesophageal reflux”  
Charlottesville, VA

9<sup>th</sup> Annual Latin American Gastroenterology Summit-May 2017  
“New Diagnostic testing in GERD”  
“Extraesophageal reflux”  
Bogota, Columbia

GALA Conference Atlanta-May 2017  
“PPI Use: How and when?”  
Atlanta, GA

Taiwan Motility Society Meeting-May 20, 2018  
“Mucosal impedance testing for GERD”

Hualien, Taiwan

Digestive Disease Week (DDW)-June 2018

Oral Presentations on “Interpretation of HRM in Clinical Practice”

Oral Presentations on “Weight loss in Achalasia is Determined by its Phenotypes”

Oral presentations on “Novel Balloon Mucosal Impedance for diagnosis of GERD and EoE”

Poster Presentations on “Duodenal mucosal impedance”

Poster Presentations on “Concordance between mucosal impedance and pH monitoring”

Poster Presentations on “Achalasia phenotype predicts weight gain post Heller Myotomy”

Poster Presentation on “Direct comparison of MI, MNBI, and impedance pH and PSPW in patients with symptoms despite therapy”

Poster Presentation on “MI pattern differentiates esophageal inflammatory disorders”

Poster Presentation on “Proteomic identification of ex-vivo achalasia esophageal specimen”

Washington DC

2018 SCSG Post DDW symposium-June 2018

“Controversies in esophagus and stomach”

“GERD and dyspepsia-why so many patients don’t respond?”

Laguna Niguel, CA

ANMS annual Meeting-July 2018

“Mucosal Impedance: Looking Outside the Box”

Milwaukee, WI

**2017:**

Annual Metro Atlanta Educational Society for Otolaryngology Meeting

“LPR; what to do?” Jan 18, 2017

Atlanta, GA

AGA Council Meeting-Jan 28<sup>th</sup>, 2017

Chair of the EGD Section of the Council

Miami, FL

38<sup>ed</sup> Annual Sisson International Workshop-February 2017

“Dysphagia”

Vail, Colorado

Curso Internacional De Motilidad Gastrointestinal-Feb 2017

“Impedance pH studies: how good are the tools?”  
“My ENT told me that I have reflux”  
“Reflux hypersensitivity: really?”  
Bogota, Columbia

Gastroenterology Grand Rounds; Mayo Clinic Arizona-March 2017  
“Extraesophageal reflux”  
Scottsdale, AZ

8<sup>th</sup> Annual Latin American Gastroenterology Summit-April 2017  
“Oropharyngeal manifestations of GERD”  
“Extraesophageal reflux”  
Guadalajara, Mexico

Gastroenterology Grand Rounds; U. Penn-April 2017  
“Laryngopharyngeal Reflux: Controversies and what to do”  
Philadelphia, PA

Digestive Disease Week (DDW)-May 2017  
Oral Presentations on “Mucosal Impedance Measurements in EoE”  
Oral Presentations on “Weight loss in Achalasia is Determined by its Phenotypes”  
Oral presentations on “Novel Balloon Mucosal Impedance for diagnosis of GERD and EoE”  
Poster Presentations on “Do All Patients with Suspected  
Chicago, IL

GALA Cleveland Conference-May 2017  
“Refractory GERD”  
Atlanta, GA

DDW Highlights Program-June 2017  
“Update on Gastric and esophageal abstracts”  
Kansas City, MO

AGA Nominating Committee Meeting-Sept. 2017  
Nominating of AGA’s next Vice President, Institute Councillors  
Washington DC

ACG Annual Scientific Meeting-October 2017  
“Refractory GERD”  
Orlando, FL

Lyon Consensus Meeting-November 2017  
“Guidelines on esophageal function testing and interpretation”  
Lyon, France

Mayo Clinic Annual GI Update Course- December 2016  
“New Diagnostic Testing in GERD”  
Scottsdale, AZ

**2016:**

16<sup>th</sup> Annual Educational Meeting in Gastroenterology-March 2016  
Cedars-Sinai Health Systems  
“Testing in GERD”  
Los Angeles, CA

37<sup>ed</sup> Annual Sisson International Workshop-February 2016  
“Cough and GERD”  
Vail, Colorado

GALA Dallas Conference-April 2016  
“Refractory GERD”  
Dallas, TX

Visiting Professor-April 2016  
UCLA Division of Gastroenterology and Hepatology  
“LPR-Is it GERD?”  
Los Angeles, CA

7<sup>th</sup> Annual Latin American Gastroenterology Summit-April 2016  
“Chronic cough: airway hypersensitivity and other pathologies”  
“Extraesophageal reflux”  
Buenos Aires, Argentina

Digestive Disease Week (DDW)-May 2016  
Oral Presentations on “Mucosal Impedance Measurements at Index  
Endoscopy Can Diagnose EoE Without the Need for Histology”  
Oral Presentations on “Mucosal Impedance Differentiates Esophageal  
Disorders Eliminating the Need for Ambulatory Monitoring”  
Oral presentations on “Mucosal Impedance in Pediatric GERD, NERD and  
EoE”

Poster Presentations on “Mucosal Impedance in Barrett’s Esophagus: Can it  
Assess Compliance with Medication? Mucosal Impedance in Barrett’s  
Esophagus: Can it Assess Compliance with Medication?”  
Poster Presentations on “Reducing Mucosal Impedance Variability by  
Ensuring Direct Contact with Esophageal Mucosa”  
Poster Presentations on “Critical Evaluation of Functional and  
Hypersensitive Esophageal Symptoms Diagnosed by pH Monitoring: It’s  
Time to Rethink What we Recommend”

San Diego, CA

GALA Cleveland Conference-June 2016  
“Refractory GERD”  
Cleveland, Ohio

ACG Eastern Regional Postgraduate Course, June 2016  
“GERD and Suboptimal Response”  
Washington DC

ANMS Annual Conference, August 2016  
“Advances in the management of extraesophageal reflux”  
San Francisco, CA

AGA Council meeting September 2016  
EGD section Chair, DDW programing  
Washington DC

Advanced Rhinology- 2016  
“GI Evaluation of EER”  
St Petersburg, FL

Annual Mexican Gastroenterology Week-November 2016  
“Evaluation of patients with extraesophageal reflux”  
Mazatlan, Mexico

Mayo Clinic Visiting Professor-December 2016  
“LPR-Real or Not?”  
Jacksonville, FL

**2015:**

GALA Dallas Conference-April 2015  
“Barrett’s Esophagus”  
Dallas, TX

ASCONA Conference-April 17-23 2015  
GERD  
Ascona, Switzerland

Digestive Disease Week (DDW)-May 2015  
Oral Presentations on “Mucosal impedance in EER”  
Oral presentations on “Achalasia”  
Poster Presentations on “Esophageal mucosal impedance”  
Poster Presentations on “Nutrition and achalasia”  
Washington DC

GALA Ft Lauderdale Conference-May 2015

“EoE”  
Ft Lauderdale, FL

ACG Midwest Regional Postgraduate Course, August 2015  
Dyspepsia  
Kansas City, Missouri

ANMS Annual Conference, August 2015  
Functional extraesophageal reflux  
Chicago, IL  
AGA Council meeting September 2015  
EGD section Chair, DDW programing  
Washington DC

GALA Chicago Conference-September 2015  
“Barrett’s Esophagus”  
Chicago, IL

American College of Gastroenterology-October 2015  
Invited speaker-Postgraduate Course  
Course Director-Pathophysiology Course  
Honolulu, Hawaii

Annual Mexican Gastroenterology Week-November 2015  
“Esophageal motility disorders”  
Queretaro, Mexico

**2014:**

GALA Dallas Conference-March 2014  
“Extraesophageal reflux”  
Dallas, TX

Digestive Disease Week (DDW)-May 2014  
Lectures for the Post graduate course and scientific sessions  
Oral Presentations on “Functional Dyspepsia”  
Oral presentations on “Sleep disorders and GI problems”  
Oral Presentations on “Esophageal mucosal impedance”  
Oral Presentations on “new treatment strategies in GERD”  
Chicago, IL

5<sup>th</sup> Annual Latin American Gastroenterology Summit-March 2014  
“Esophageal motility disorders”  
“Extraesophageal reflux”  
Lima, Peru

Medicine and Gastroenterology Grand Rounds-Univ Chicago-March 2014  
“LPR-how to diagnose and treat”

“GERD-pathophysiology”  
Chicago, IL

GALA Miami Conference-March 2014  
“Refractory GERD”  
Miami, FL

Annual Meeting on Esophageal and Foregut Disorders-February 2014  
“Diagnostic approach to patients with GERD”  
“EER and LPR”  
“Treatment options in EER”  
“PPI’s and ASA in Barrett’s esophagus”  
Mauna Lani, Hawaii

AGA Clinical Congress—January 2014  
“Refractory GERD-What Does it Mean?”  
Miami, FL

**2013:**

American College of Gastroenterology Regional Course-December 2013  
Invited speaker  
“Extraesophageal GERD”  
Nashville, TN

American College of Gastroenterology-October 2013  
Invited speaker-Postgraduate Course  
Course Director-Pathophysiology Course  
San Diego, CA

7<sup>th</sup> Annual Gastroenterology Update Vanderbilt; September 2013  
“Eosinophilic Esophagitis”  
Nashville, TN

17<sup>th</sup> Annual Neurogastroenterology and motility Society-September 2013  
Invited speaker: “Novel Testing for GERD”  
Huntington Beach, CA

30<sup>th</sup> Annual Gastroenterology Week- September 2013  
“GERD and EER”  
Istanbul, Turkey

University of Manitoba Gastroenterology Update-May 2013  
Invited speaker on “Extraesophageal Reflux”  
University of Manitoba GI Dept.  
Manitoba, Canada

Digestive Disease Week (DDW)-May 2013

Oral Presentations on “Predictors of response in patients with chronic cough”  
Oral Presentations on “Esophageal mucosal impedance”  
Orlando, FL

35<sup>ed</sup> Annual Sisson International Workshop-February 2012  
“Is GERD the same as LPR?”  
Vail, Colorado

AGA Winter Course—January 2013  
“Refractory GERD”  
San Diego, CA

**2012:**

Gastroenterology Summit; November 2012  
“Extraesophageal GERD”  
Merida, Mexico

Panamerican GI Society Meeting-November 2012  
Invited speaker: “EERD”  
Panama City, Panama

6<sup>th</sup> Annual Vanderbilt Gastroenterology Update- September 2012  
“GERD and Chronic Cough”  
Vanderbilt University Medical Center  
Nashville, TN

12<sup>th</sup> Biennial Phonosurgery Symposium-July 2012  
Invited speaker on “LPR”  
University of Wisconsin ENT Dept.  
Madison, WI

Digestive Disease Week (DDW)-May 2012  
Invited Reviewer for AGA-“Motility disorders”  
Invited Presentations on “What to do with Extraesophageal GERD”  
San Diego, CA

3<sup>ed</sup> Annual Mexican Gastroenterology Submit-May 2012  
“Significance of reflux in EER.”  
Merida, Mexico

12<sup>th</sup> Annual Educational Meeting in Gastroenterology -March 2012  
“Complications of PPI Therapy”  
Cedars Sinai Medical Center  
Los Angeles, CA

34<sup>ed</sup> Annual Sisson International Workshop-February 2012



“Is GERD the same as LPR?”  
Vail, Colorado

Gastroenterology Grand rounds-Vanderbilt-February 2012  
“GERD”  
Nashville, TN

**2011:**

American College of Gastroenterology-October 2011  
Invited speaker-Postgraduate Course  
Course Director-Pathophysiology Course  
“GERD and obesity”  
“Refractory GERD”  
Washington, DC

American Neuromotility Society-September 2011  
Invited speaker: “GERD and EERD”

The Gastroenterology Foundation of South Africa-September 2011  
Invited speaker for national meeting  
“A multidisciplinary approach to reflux disease”  
Cape Town South Africa

Nashville Aphasiology Group-May 2011  
Invited speaker on “EERD and dysphagia”

Digestive Disease Week (DDW)-May 2011  
Invited Reviewer for AGA-“EERD”  
Invited Presentations on “Extraesophageal GERD”  
Invited Presentation on “Refractory GERD”  
Chicago, IL

Annual Meeting of the SSORL-HNS-April 2011  
Extraesophageal GERD  
Interlaken, Switzerland

ENT Grand rounds-Emory-March 2011  
LPR: “What is it and the unknown?”  
Atlanta, GA

Medicine Grand rounds-Hamilton Medical Center -February 2011  
“Controversial Issues with PPI’s”  
Dalton, GA

33<sup>ed</sup> Annual Sisson International Workshop-February 2011  
“Extra-esophageal reflux: Many diseases wrapped in one”  
Vail, Colorado

Gastroenterology Grand rounds-Vanderbilt-January 2011  
“Esophageal function testing”  
Nashville, TN

2010:

American Speech-Language Hearing Association-November 2010  
Update in LPR  
Philadelphia, PA

Mexican Association of Gastroenterology-November 2010  
GERD and minimal change in physiologic tests  
Barrett’s esophagus  
Extraesophageal GERD  
Bile reflux  
Acapulco, Mexico

Advanced Techniques in Endoscopic Management of Sinonasal Disorder-  
November 2010  
Extraesophageal GERD  
St. Petersburg, FL

UEGW Annual Meeting-October 2010  
Extraesophageal GERD: Have we made progress?  
Barcelona, Spain

Vanderbilt Digestive Disease ”Gastroenterology Update”-September 2010  
Medical Therapy for Barrett’s Esophagus  
Nashville, TN

American Neurogastroenterology and Motility Society Annual Meeting-  
August 2010  
Catheter Based pH Monitoring  
Boston, MA

Annual Venezuelan Gastroenterology Congress-August 2010  
Refractory GERD  
Caracas, Venezuela

Digestive Disease Week (DDW)-May 2010  
Invited Reviewer for SSAT-“EERD”  
Presentations on “Extraesophageal GERD”  
Chaired a session on “Refractory GERD”  
Invited presentation on “PPI Adverse Effects”  
New Orleans, LA

Suny Downstate Medical Center GI Grand Rounds-April 2010  
Esophageal Function Testing  
Brooklyn, NY

32<sup>nd</sup> Annual Sisson International Workshop-February 2010  
LPR: "What else can it be?"  
Vail, Colorado

American Gastroenterological Association Clinical Congress -January 2010  
Esophageal Physiology Testing  
Las Vegas, Nevada

**2009:**

Annual Mexican Gastrointestinal Conference-December 2009  
Bile Reflux  
Guadalajara, Mexico

American College of Gastroenterology Meeting- October 2009  
Course Director-GI Pathophysiology  
Cough and GERD

Voice and Swallowing Disorders Course-October 2009  
LPR: Is it Real?  
Riyadh, Saudi Arabia

4<sup>th</sup> Annual GI Update Course-Vanderbilt-September 2009  
Eosinophilic Esophagitis  
Nashville, TN

Eastern Virginia Medical School Annual Course-June 2009  
Extraesophageal GERD  
Virginia Beach, VA

Gastroenterology Grand Rounds-Vanderbilt-July 2009  
Esophageal Motility Disorders  
Nashville, TN

University of Cincinnati Annual DDW Update-June 2009  
Esophageal Diseases  
Cincinnati, OH

National Meeting for the American Nurse Practitioners-June 2009  
GERD  
Nashville, TN  
Digestive Disease Week (DDW)-May 2009

Postgraduate Course Lecture-“EERD”  
Chaired a session on “Extraesophageal GERD”  
Chaired a session on “Refractory GERD”  
Invited presentation on “EERD and Esophageal Function Testing”  
Meet the Professor Luncheon-Extraesophageal GERD  
Chicago, IL

8<sup>th</sup> Annual Otolaryngology Symposium-April 2009  
LPR: Controversies and Consensus  
Ponte Vedra Beach, FL

Fifth International Course on Gastrointestinal Motility-April 2009  
1) GERD and Obesity  
2) Chest pain of Esophageal Origin  
3) Laryngeal Manifestation of GERD  
4) Role of Impedance Monitoring in Refractory GERD  
Bogota, Colombia

Internal Medicine Lecture Series-Vanderbilt-April 2009  
Esophageal Motility Disorders  
Nashville, TN

GI Grand Rounds-Winthrop Hospital-March 2009  
Impedance Monitoring and HRM  
Long Island, NY

Dysphagia Research Society Annual Meeting-March 2009  
1) Techniques to Measure Retrograde Bolus Transport  
2) Rumination Syndrome  
3) LPR: point counter point  
New Orleans, LA

31<sup>st</sup> Annual Sisson International Workshop-February 2009  
LPR: “See It My Way”  
Vail, Colorado

**2008:**

GI and Medicine Grand Rounds-MUSC-October 2008  
New Tests in Acid Reflux/Atypical GERD  
Charleston, GA

8<sup>th</sup> Brazilian Digestive Disease Week-October 2008  
LPR/Impedance Monitoring  
Brasilia, Brazil  
American Academy of Otolaryngology-Head and Neck Surgery  
September 2008

Controversies in LPR  
Chicago, IL

Annual GI Update-Vanderbilt University-September 2008  
Beyond GERD  
Nashville, TN

11<sup>th</sup> World Congress of the ISDE-September 2008  
Extraesophageal Reflux Disease  
Budapest, Hungary

South Region ASGE First Year Fellows' Endoscopy Course-August 2008  
Diagnostic Endoscopy/Electrocautery 101  
Oak Brook, IL

Southern California Society of Gastroenterology  
Post DDW Meeting-July 2008  
Esophageal Disease update/LPR  
Dana Point, CA

University of Cincinnati Annual DDW Update-June 2008  
Update in Esophageal Diseases  
Cincinnati, OH

Mayo Clinic Research Grand Rounds-June 2008  
Invited lecture on Achalasia  
Rochester, MN

Digestive Disease Week (DDW)-May 2008  
Chaired a session on Extraesophageal GERD  
Chaired a session on GERD  
Invited presentation on non-obstructive Dysphagia  
Meet the Professor Luncheon-extraesophageal GERD  
San Diego, CA

Combined Otolaryngology Spring Meeting (COSM) – May 2008  
Chaired a session on “controversies in LPR”  
Orlando, FL

Annual Gastroenterology Update-2008; April 2008  
University of North Carolina –Division of Gastroenterology  
Chapel Hill, NC

Medicine Grand Rounds-April 2008  
St. Francis Health Center; Topeka KS  
Atypical GERD

Specialty training for GI fellows-March 2008  
Motility and pH testing/ENT manifestations of GERD  
Cork, Ireland

American Motility Society-March 2008  
Eosinophilic esophagitis/esophageal function testing  
Atlanta, GA  
National Sisson Meeting – Otolaryngology Association-February 2008  
Vail, Colorado  
Chaired a Committee on LPR

**Resident/Fellow Education:**

Internal Medicine Board Review lectures on esophageal diseases since 1999

Research mentor to 56 residents and 28 GI fellows since 2001  
(resulting in peer reviewed publications at national meetings)

Annual lectures to fellows and residents on esophageal diseases

**Mentored Students/Residents/Fellows:**

Medical Student:

Pranav Santapuram-- Vanderbilt University Medical School

Trisha Pasricha--Vanderbilt University Medical School

Dilan Patel---Memphis University Medical School

Jennifer Rymer--Vanderbilt University Medical School--now Resident at Duke

Christopher Hom-Meharry Medical School; applying for residency

Samuel Aznaurov-Vanderbilt University Medical School

Michelle Law-Vanderbilt University Medical School

Hannah Kim-Vanderbilt University Medical School

Meredith Brandt-Vanderbilt University Medical School

Residents:

Mohammad Qadeer--Mentored during Residency and fellowship in GI---Gastroenterologist

Dhyanesh Arvind Patel-Resident, Vanderbilt

Brian Lappas-Resident, Vanderbilt University

Meera Reddy Wright-Resident, Vanderbilt University  
Rishi Naik- Resident, Vanderbilt University  
Joseph Krill-Resident Vanderbilt University  
Hannah Kim- Resident Vanderbilt University  
Lawrence Heller- Resident Vanderbilt University  
Jerry Zifodya- Resident Vanderbilt University  
Aberra Fasica-Resident Vanderbilt University  
Wheaton Fransiscan Health Care; Chicago  
Anas Abou-Ismael--Vanderbilt University Medical Center  
David Barry- Vanderbilt University Medical Center  
Rishi Naik- Vanderbilt University Medical Center  
Zurabi Lominadz--Vanderbilt University Medical Center  
Puneet Mishra--Vanderbilt University Medical Center  
William Ergen-Vanderbilt University Medical Center  
Fasika Aberra- Vanderbilt University Medical Center  
Zurabi Lominadze-Vanderbilt University Medical Center  
Ameke Oranu---Meharry College; now a research fellow at Harvard  
Afrin Kamal--Vanderbilt University Medical Center now at Barnes Jewish Medical Center  
John Moore—Vanderbilt University Medical Center now a fellow in GI at MUSC  
David Barry—Vanderbilt University Medical Center now a fellow in GI at Wake Forest  
George Sun— Vanderbilt University Medical Center now in San Antonio as a  
gastroenterologist  
Eric Hill—Vanderbilt University Medical Center now at Digestive Health Associated in  
North Richland Hills, Texas  
Sean Casey-Vanderbilt University Medical Center now at Vanderbilt University  
Farnoosh Farrokhi—now an endocrinologist at Emory University  
Jason Pritchett—Vanderbilt University Medical Center not at Vanderbilt  
Jannette Frye-Vanderbilt University Medical Center now at UVA as a GI fellow  
Jason Swoger- At Cleveland Clinic now at university of Pittsburgh  
Tasneem Ahmed-at Cleveland Clinic now in Dallas TX  
Saeed Khatemi-at the Cleveland Clinic now at Mentor OH

David Nayar-at the Cleveland Clinic now at Edison NJ Gastroenterology  
Samer Charbel at the Cleveland Clinic now at Digestive Disease Center of Southern GA  
Talal Adhami at the Cleveland Clinic now faculty at the Cleveland Clinic  
Kaveh Farhoomand at the Cleveland Clinic now at Oceanside CA  
Tuba Esfandyari at the Cleveland Clinic now faculty at University of Kansas

Fellows:

Rohit Sharda-current fellow in GI  
Dan Patel-current fellow in GI  
Yash Choksi-current fellow in GI  
Allyson Lowry-current fellow in Peds GI  
Rob Kavitt-now Director of Swallowing Center at University of Chicago  
Eric Sumner-----now faculty at Vanderbilt University Medical Center  
Brad Shepherd----now in private practice; GI  
Jon Scheider-----now faculty at Frist Clinic at Nashville  
Sam Hong---Oklahoma University Medical center  
Brian Smith—now at Piedmont Gastroenterology  
David Francis---ENT fellow in Laryngology--now faculty at the Vanderbilt Voice Center  
Sara Rippel---Pediatric GI fellow---now in Jackson MS  
Ken Fletcher---ENT fellow in Laryngology--now at Greater Baltimore Medical Center  
Sri Muddana-Fellow at Vanderbilt now at University of Massachusetts Worcester Campus  
Michael Falcone—Fellow at the Voice Center at Vanderbilt now in Charlotte NC  
Mohammad Aslam—Research fellow now Research faculty at Vanderbilt University  
Woosuk Park-at the Cleveland Clinic now at Racine WI

Visiting Internist/Gastroenterologist Training:

Katarina Greer, Case Western Reserve Faculty  
Pooja Lal, MD, Visiting physician, Pakistan  
Elif Saritas Yuksel, MD, Visiting Gastroenterologist-Turkey  
Fehmi Ates, MD, Visiting Gastroenterologist-Turkey  
Farnoosh Farrokhi, MD, Visiting physician, Iran



## PEER REVIEWED PUBLICATIONS:

1. Hope, K.D., Robinson, C.Y., Vaezi, M.F., Brouillette, W.J., Muccio, D.D. <sup>13</sup>C NMR assignments of the isoprenoid chain carbons of retinoids from empirical Chemical Shift Differences. *Magn. Reson. Chem.* 1987; 25, 1040-1045.
2. Vaezi, M.F., Robinson, C.Y., Hope, K.D., Brouillette, W.J., Muccio, D.D. Preparation of the 9-cis and all-trans-Isomers  $\alpha$ - and  $\beta$ 2-Retinal. *Org. prep. Proc. Int.* 1987; 19, 187-195.
3. Vaezi, M.F., Synthesis of retinal analogues and studies on the corresponding Bacteriorhodopsin pigments. Ph.D. Dissertation, 1989.
4. Vaezi, M.F., Alam, M., Sani, B.P., Rogers, T.S. et al. A conformationally defined 6-s-trans retinoic acid isomer: Synthesis, chemopreventive activity and toxicity. *J. Med. Chem.* 1994; 37:4499-4507.
5. Vaezi, M.F., Brouillette, W.J., Muccio, D.D. <sup>13</sup>C NMR assignments of conformationally defined 6-s-trans retinoids. *Mag. Res. Chem.* 1995; 33:497-499.
6. Muccio, D. D., Alam, M., Vaezi, M.F., et al. Conformationally defined 6-s-trans retinoic acid analogues: structure activity relationships for nuclear receptor binding, transcriptional activity and cancer chemopreventive activity. *J. Med. Chem.* 1996; 39, 3625-3635.
7. Champion, G., Richter, J.E., Vaezi, M.F., Singh, S., Alexander, R. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus. *Gastroenterology*, 1994; 107:747-754.
8. Vaezi, M.F., LaCamera, R.G., and Richter, J.E. Validation studies of the Bilitec 2000: An ambulatory duodenogastric reflux monitoring system. *Am. J. Physiol.* 1994; 30:G1050-57.
9. Vaezi, M.F., Richter, J.E. Fiberoptic sensor for bilirubin. *Am. J. Surg.*, 1995; 170:310-312.
10. Vaezi, M.F., Rustagi, P.K., Elson, C.O. Transient Protein S Deficiency in a Patient with Acute Ulcerative Colitis, *Am. J. Gastroenterol.*, 1995; 90:313-315.
11. Schroeder, P.L., Filler, S.J., Ramirez, B., Lazarchik, D.A., Vaezi, M.F., Richter, J.E. Dental erosion: Relationship to GERD confirmed by pH monitoring. *Ann. Int. Med.* 1995; 122:809-815.
12. Vaezi, M.F., Richter, J.E. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. *Surgery* 1995; 117:699-704.

13. Vaezi, M.F., Singh, S., Richter, J.E. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. *Gastroenterology* 1995; 108:1897-1907.
14. Vaezi, M.F., Sears, R., Richter, J.E. Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. *Dig. Dis. Sci.*, 1996; 41:754-763.
15. Vaezi, M.F., Richter, J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. *Gastroenterology* 1996; 111:1192-1199.
16. Vaezi, M.F., Richter, J.E. 24-hour ambulatory esophageal pH monitoring in the diagnosis of acid reflux-related chronic cough. *South. Med. J.*, 1997; 90:305-311.
17. Vaezi, M.F., Schroeder, P.L., Richter, J.E. Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring. *Am J Gastroenterol* 1997; 92:825-829.
18. Vaezi, M.F., Richter, J.E. Contribution of acid and duodenogastroesophageal reflux to esophageal mucosal injury and symptoms in partial gastrectomy patients. *Gut* 1997; 41:297-302.
19. Vaezi, M.F., Falk, G.F., Richter, J.E. *Helicobacter pylori* and gastroesophageal reflux disease. The bug may not be all bad. *Am J Gastroenterol* 1998; 93:1800-1802.
20. Ormsby, A.H., Goldblum, J.R., Rice, T.W., Richter, J.E., Vaezi, M.F., Gramlich, T.L. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. *Human Pathology* 1999; 30:288-294.
21. Peek, R.M., Vaezi, M.F., Falk, G.W., Goldblum, J.R., Perez-Perez, G.I., Richter, J.E., Blaser, M.J. The role of *Helicobacter pylori* *cagA*<sup>+</sup> strains and specific host immune responses on the development of pre-malignant and malignant lesions in the gastric cardia. *Int J Cancer* 1999; 82:520-24.
22. Vaezi, M.F., Baker, M.E., Richter, J.E. Assessment of esophageal emptying post-pneumatic dilation: use of the timed barium esophagram. *Am J Gastroenterol* 1999; 94:1802-1807.
23. Vaezi, M.F., Richter, J.E., Wilcox, C.M., Schroeder, P.L., Birgisson, S., Slaughter, R.L., Koehler, R.E., Baker, M.E. Botulinum toxin vs pneumatic dilation in the treatment of achalasia: a randomized trial. *Gut* 1999; 44:231-239.
24. Vaezi, M.F., Falk, G.W., Peek, R.M., Vicari, J.J., Goldblum, J.R., Perez-Perez GI, Rice, T.W., Blaser, M.J., Richter, J.E. Cag A positive strains of *Helicobacter pylori* may protect against Barrett's esophagus. *Am J Gastroenterol* 2000; 95: 2206-2211.

25. Ormsby, A.J., Vaezi, M.F., Goldblum, J.R., Richter, J.E., Gramlich, T.L. Cytokeratin immunoreactivity patterns in the diagnosis of short segment Barrett's esophagus. *Gastroenterology* 2000; 119:683-690.
26. Imperiale, T.F., O'Connor, J.B., Vaezi, M.F., Richter, J.E. The cost-effectiveness of treatment strategies for Achalasia. *Am J Gastroenterol* 2000; 95:2737-45
27. Fackler, W.K., Vaezi, M.F., Richter, J.E. Ambulatory gastric pH monitoring: proper probe placement and normal values. *Aliment Pharm Therap.* 2001;15:1155-62.
28. O'Connor, J.B., Singer, M.E., Imperiale, T.F., Vaezi, M.F., Richter, J.E. The cost effectiveness of treatment strategies for achalasia. *Dig Dis Sci* 2002; 47:1516-1525.
29. Goldblum, J.R., Richter, J.E., Vaezi, M.F., Falk, G.W., Rice, T.W., Peek, R.M. Helicobacter Pylori infection, not gastroesophageal reflux is the major cause of inflammation and intestinal metaplasia of the native gastric cardia. *Am J Gastroenterol.* 2002; 97:302-11.
30. Vaezi, M.F., Baker, M.E., Achkar, E., Richter, J.E. Timed-barium esophagram: better predictor of long-term success post-pneumatic dilation in achalasia than symptom assessment. *Gut* 2002; 50:765-770.
31. Esfandyari, T., Potter, J.W., Vaezi, M.F.. Dysphagia: a cost analysis of the diagnostic approach. *Am J Gastroenterol* 2002; 97:2733-7.
32. Fackler, W.K., Ours, T.M., Vaezi, M.F., Richter, J.E. Long-term effect of H2RA's therapy on nocturnal gastric acid breakthrough. *Gastroenterology* 2002; 122:625-32.
33. Hicks, D.M., Vaezi, M.F., Ours, T.M., Richter, J.E. ENT signs of GERD. *J Voice*, 2002; 16:564-579.
34. Ours, T.M., Fackler, W.K., Richter, J.E., Vaezi, M.F. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. *Am J Gastroenterol* 2003; 98:545-550.
35. Vaezi, M.F., Hicks, D.M., Abelson, T.I., Richter, J.E. Laryngeal signs and symptoms and gastroesophageal reflux disease: a critical assessment of cause and effect association. *Clin Gastroenterol Hepatol* 2003; 1:333-44.
36. Vaezi, M.F. Laryngitis and gastro-esophageal reflux disease (GERD): improve laryngoscopic specificity, don't do pH monitoring. *Dig. Liver Dis.* 2004; 36:103-104.

37. Adhami, T., Goldblum, J.R., Richter, J.E., Vaezi, M.F. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. *Am J Gastroenterol* 2004; 99:2098-106.
38. Farhoomand, K., Connor, J.T., Achkar, E., Richter, J.E., Vaezi, M.F. Predictors of outcome of pneumatic dilation in achalasia. *Clin Gastroenterol Hepatol* 2004; 2004 May;2(5):389-94.
39. Vaezi, M.F. Laryngitis and Gastroesophageal reflux disease (GERD): Increasing prevalence or poor diagnostic tests? (Editorial) *Am J Gastroenterol* 2004; 99:786-8
40. Vaezi, M.F. Refractory GERD; acid, non-acid or not GERD? (Editorial) *Am J Gastroenterol* 2004; 99:989-90.
41. Charbel, S., Khandwala, F., Vaezi, M.F. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. *Am. J. Gastroenterol.* 2005; 100:283-9.
42. Nayar, D., Khandwala, F., Achkar, E., Shay, S., Richter, J.E., Falk, G., Soffer, E., Vaezi, M.F. Esophageal manometry: assessment of interpreter consistency. *Clin. Gastroenterol Hepatol* 2005; 3:218-24.
43. Park, W., Vaezi, M.F. Etiology and pathogenesis of achalasia: the current understanding. *Am J Gastroenterol.* 2005; 100:1404-14.
44. Park, W., Hicks, D.M., Khandwala, F., Richter, J.E., Abelson, T.I., Milstein, C., Vaezi, M.F. Laryngopharyngeal reflux (LPR): Prospective cohort study evaluating optimal dose of ppi therapy and pre-therapy predictors of response. *Laryngoscope* 2005; 115:1230-8.
45. Maqbool, S., Bhat, Y.M., Ours, T.M., Oldenburgh, M., Vaezi, M.F. Dose response of acid and duodenogastroesophageal reflux (DGER) to Rabeprazole in patients with Barrett's Esophagus. *Am J Gastroenterology* 2005; in review.
46. Khatemi, S., Shay, S., Vaezi, M.F. Does DES progress to achalasia? A prospective cohort study. *Dig Dis Sci.* 2005; 50:1605-10.
47. Qadeer, M., Colabianchi, N., Vaezi, M.F. Response: Is GERD a risk factor for laryngeal cancer? A meta analysis. *The laryngoscope* 2005; 115:486-91.
48. Qadeer, M., Colabianchi, N., Strome, M., Vaezi, M.F. GERD and laryngeal cancer: Causation or association? a critical review. *Am J Otolaryngol.* 2006; 101:470-8.
49. Swoger, J., Ponsky, J., Hicks, D.M., Richter, J.E., Abelson, T.I., Milstein, C., Vaezi, M.F. surgical fundoplication in laryngopharyngeal reflux (LPR) unresponsive to aggressive acid suppression: a prospective concurrent controlled study. *Clin Gastroenterology Hepatol* 2005; in press.

50. Qadeer, M., Colabianchi, N., Vaezi, M.F. Laryngeal cancer and gastroesophageal reflux disease: a case control study. *Am J Med* 2005; in review
51. Qadeer, M.A., Lopez, R., Wood, B.G., Esclamado, R., Strome, M., Vaezi, M.F. Does acid suppressive therapy reduce the risk of laryngeal cancer recurrence? *Laryngoscope* 2005, 115:1877-81.
52. Vaezi, M.F., Richter, J.E., Stasney, C.R., Spiegel, J.R., Iannuzzi, R.A., Crawley, J.A., Hwang, C., Sostek, M.B., Shaker, R. Treatment of chronic posterior laryngitis with esomeprazole: Placebo controlled trial. *Laryngoscope* 2006; 116:254-60.
53. Qadeer, M.A., Swoger, J., Milstein, C., Hicks, D.M., Richter, J.E., Ponsky, J., Abelson, T.I., Vaezi, M.F. Correlation between symptoms and laryngeal signs in laryngopharyngeal reflux (LPR): A prospective study. *Laryngoscope* 2005; 115:1947-52.
54. Milstein, C., Charbel, S., Hicks, D.M., Richter, J.E., Abelson, T.I., Vaezi, M.F. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: Impact of endoscopic technique (rigid vs. flexible scope). *Laryngoscope* 2005; 115:2256-61.
55. Rice, T., McKelvey, A., Richter, J.E., Baker, M., Vaezi, M.F., Feng, J., Murthy, S., Mason, D., Blackstone, E. A physiologic clinical study of achalasia. Should fundoplication be added to Heller myotomy? *J Thorac Cardio Vasc Surg.* 2005; 130:1593-1600.
56. Ahmed, T., Khandwala, F., Abelson, T.I., Hicks, D., Richter, J.E., Milstein, C., Vaezi, M.F. Chronic Laryngitis associated with GERD: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians. *Am J Gastroenterol.* 2006 Mar;101 (3):470-8.
57. Swoger, J., Ponsky, J., Hicks, D.M., Richter, J.E., Abelson, T.I., Milstein, C., Qadeer, M.A., Vaezi, M.F. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. *Clin Gastroenterology Hepatol.* 2006 Apr; 4(4):433-41.
57. Vaezi, M.F. Should we bravo? *Gastroenterology.* 2006 Jun; 130(7):2238-9.
58. Vaezi, M.F., Qadeer, M.A., Lopez, R., Colabianchi, N. Laryngeal cancer and gastroesophageal reflux disease: a case-control study. *Am J Med.* 2006 Sep;119(9):768-76.
59. Qadeer, M.A., Phillips, C.O., Lopez, A.R., Steward, D.L., Noordzij, J.P., Wo, J.M., Suurna, M., Havas, T., Howden, C.W., Vaezi, M.F. Proton pump inhibitor therapy for suspected

- GERD-related laryngitis: a meta analysis of randomized controlled trials. *Am J Gastroenterol.* 2006 Nov; 101(11):2646-54.
60. Vaezi, M.F. Treatment with PPIs should not be preceded by pH monitoring in laryngeal reflux. *Am J Gastroenterol* 2006; 101:8-10.
  61. Vaezi, M.F. We should learn from important negative results. *Laryngoscope* 2006;116:1718.
  62. Vaezi, M.F. Role of impedance pH monitoring in refractory GERD; Let's be careful out there. *Gastroenterology* 2007; 132:1621-28.
  63. Vaezi, M.F. Are there specific laryngeal signs for GERD? *Am J Gastroenterol* 2007; 723-24.
  64. Vaezi, M.F. Sore throat and a red hypopharynx: is it reflux? *Clin Gastroenterology Hepatology* 2007 Dec; 5(12):1379-82.
  65. Vaezi, M.F. GERD and Obesity: a real BIG issue! *Gastroenterology* 2008 Mar; 134(3): 882-3.
  66. Dent, J., Kahrilas, P.J., Vakil, N., Veldhuyzen van Zanten, S., Bytzer, P., Delaney, B., Haruma, K., Hatlebakk, J., McColl, E., Moayyedi, P., Stanghellini, V., Tack, J., Vaezi, M.F. Clinical trial design in adult reflux disease: a methodological workshop. *Alimentary Pharmacology & Therapeutics* 2008; 28 (1): 107–126.
  67. Kahrilas, P.J., Shaheen, N.J., Vaezi, M.F. American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. *Gastroenterology* 2008 Oct; 135 (4): 1392-1413.
  68. Kahrilas, P., Shaheen, N., Vaezi, M.F. AGA medical position statement on the management of gastroesophageal reflux disease. *Gastroenterology* 2008; 135:1383-1391.
  69. Winter, H.S., Illueca, M., Vaezi, M.F. Is there a relationship between gastroesophageal reflux disease in pediatrics and that in adulthood? *Clin Gastroenterol Hepatol.* 2008-(In Review).
  70. Vaezi, M.F. Should surgery replace pneumatic dilation in achalasia? *Gastroenterology* 2008 Nov; 135(5): 1794-6.
  71. Nafar, M., Farrokhi, F, Vaezi, M.F., Entezari, A.W., Pour-Reza Gholi, F., Firoozan, A., Eniollahi, B. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. *Int Urol Nephrol.* 2009; 41 (3): 687-93.

72. Wiener, G.J., Tsukashima, R., Kelly, C., Wolf, E., Schmeltzer, M., Bankert, C., Fisk, L., Vaezi, M. Oropharyngeal pH Monitoring for the Detection of Liquid and Aerosolized Supraesophageal Gastric Reflux. *Laryngoscope*. 2009; 23: 498-504.
73. Pritchett J.M., Aslam, M., Slaughter, J.D., Ness, R.M., Garrett, C.G., Vaezi, M.F. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. *Clin Gastroenterology Hepatology* 2009 Jul; 7 (7): 743-8.
74. Falcone, M.T., Garrett, C.G., Slaughter, J.C., Vaezi, M. Transnasal esophagoscopy findings: interspecialty comparison. *Otolaryngology Head Neck Surg*. 2009 Jun; 140 (6): 812-5.
75. Sun, G., Muddana, S., Slaughter, J.C., Casey, S., Hill, E., Farrokhi, F., Garrett, C.G., Vaezi, M.F. A new pH catheter for Laryngopharyngeal reflux: Normal values. *Laryngoscope* 2009 Aug; 119 (8): 1639-43.
76. Lacy BE, Weiser K, Chertoff J, Fass R, Pandolfino JE, Richter JE, Rothstei RI, Spangler C, Vaezi MF. The diagnosis of gastroesophageal reflux disease. *Am J Med* 2010; 123:583-92.
77. Vaezi MF. Benefit of acid suppressive therapy in chronic laryngitis: the devil is in the details. *Clin Gastroenterol Hepatol* 2010; 8:741-2.
78. Vaezi MF, Slaughter JC, Smith BS, Washington MK, Jerome WG, Garrett CG, Hagaman D, Goutte M. Dilated intercellular space in chronic laryngitis and GERD: at baseline and post lansoprazole therapy. *Aliment Pharmacol Therap.* 2010; 32:916-24.
79. Vaezi MF, Hagaman DD, Slaughter JC, Tanner SB, Duncavage JA, Allocco CT, Sparkman C, Clement LE, Wasden CM, Wirth D, Goutte M, McCafferty BA, Lanza DC. Proton pump inhibitor therapy improves symptoms in post nasal drainage. *Gastroenterology* 2010; 139:1887-1893.
80. Altman KW, Prufer N, Vaezi MF. The Challenge of protocols for reflux disease: a review and development of critical pathway. *Otolaryngol Head Neck Surg* 2011; in press.
81. Altman KW, Prufer N, Vaezi MF. A review of clinical practice guidelines for reflux disease: toward creating a clinical protocol for the otolaryngologist. *Laryngoscope* 2011: 121:717-23.
82. Winter HS, Illueca M, Henderson C, Vaezi MF. Review of the persistence of gastroesophageal reflux disease in children, adolescents and adults: does gastroesophageal reflux disease in adults sometimes begin in childhood? *Scan J Gastroenterol* 2011, 46:1157-68.
83. Slaughter JC, Goutte M, Rymer JA, Oranu AC, Schneider JA, Garrett CG, Hagaman D, Vaezi MF. Caution about over-interpretation of symptom indexes in reflux monitoring for refractory GERD. *Clin Gastroenterol Hepatol.* 2011, 9:868-74.

84. Francis DO, Goutte M, Slaughter JC, Garrett CG, Hagaman D, Holzman MD, Vaezi MF. Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux. *Laryngoscope* 2011; 121:1902-9.
85. Fletcher KC, Goutte M, Slaughter JC, Garrett CG, Vaezi MF. Significance and degree of reflux in patients with primary extraesophageal symptoms. *Laryngoscope* 2011; 121:2561-5.
86. Francis DO, Sumner E, Goutte M, Garrett CG, Hagaman D, Vaezi MF. Feasibility of dual wireless esophageal pH monitoring: randomized blinded sham-controlled trial. *Otolaryngol Head Neck Surg* 2012; 147:91-7.
87. Rippel SW, Acra S, Correa H, Vaezi M, Di Lorenzo C, Walker LS. Pediatric Patients with Dyspepsia Have Chronic Symptoms, Anxiety, and Lower Quality of Life as Adolescents and Adults. *Gastroenterology*. 2012; 142; 754-61.
88. Aslam M, Slaughter JC, Goutte M, Garrett CG, Hagaman D, Vaezi MF. Non-Linear Relationship Between Body Mass Index and Esophageal Acid Exposure in the Extraesophageal Manifestations of Reflux. *Clin Gastroenterol Hepatol*. 2012; 10:874-8.
89. Yuksel ES, Hong SS, Strugala V, Slaughter JC, Goutte M, Garrett CG, Dettmar PW, Vaezi MF. Rapid Salivary Pepsin Test: Blinded Assessment of Test Performance in GERD. *Laryngoscope* 2012; 122:1312-6.
90. Yuksel ES, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, Garrett CG, , Vaezi MF. Use of direct endoscopic guided measurement of mucosal impedance in diagnosis of GERD. *Clin Gastroenterol Hepatol*; 2012; 10:1110-6.
91. Kavitt RT, Penson DF, Vaezi MF. Eosinophilic esophagitis: dilate or medicate? A cost analysis mode of the choice of initial therapy. *Dis Esophagus*; 2012.
92. Kavitt RT, Higginbotham T, Slaughter JC, Patel D, Yuksel ES, Lominadze Z, Abou-Ismaïl A, Pasricha T, Garrett CG, Hagaman D, Vaezi MF. Symptom reports are not reliable during ambulatory reflux monitoring. *Am J Gastroenterol* 2012; 107: 1826-32.
93. Gyawali CP, Bredenoord AJ, Conklin JL, Fox M, Pandolfino JE, Peters JH, Roman S, Staiano A, Vaezi MF. Evaluation of esophageal motor function in clinical practice. *Neurogastroenterol Motil* 2013; 25:99-133.
94. Jobe BA, Richter JE, Hoppo T, Peters JH, Bell R, Dengler WC, Devault K, Fass R, Gyawali CP, Kahrilas PJ, Lacy BE, Pandolfino JE, Patti MG, Swanstrom LL, Kurian AA, Vela MF, Vaezi M, Demeester TR. Preoperative Diagnostic Workup before Antireflux Surgery: An Evidence and Experience-Based Consensus of the Esophageal Diagnostic Advisory Panel. *J Am Coll Surg*. 2013 Aug 21. doi:pii: S1072-7515(13)00424-9. 10.1016/j.jamcollsurg.2013.05.023. [Epub ahead of print].



95. Vaezi MF, Kahrilas PJ. Barrett's esophagus surveillance. Time to rethink if one size fits all? *Gastroenterology* 2013; 145: 503-5.
96. Vaezi MF, Pandolfino JE, Vela MF. ACG Clinical Guideline: Diagnosis and management of Achalasia. *Am J Gastroenterol* 2013; 108:1238-49.
97. Kavitt RT, Yuksel ES, Slaughter JC, Gaelyn Garrett C, Hagaman D, Higginbotham T, Vaezi MF. The role of impedance monitoring in patients with extraesophageal symptoms. *Laryngoscope*. 2013 Jul 15. doi: 10.1002/lary.23734. [Epub ahead of print].
98. Gyawali CP, Bredenoord AJ, Conklin JL, Fox M, Pandolfino JE, Peters JH, Roman S, Staiano A, Vaezi MF. Esophageal high resolution manometry in a community practice. *Neurogastroenterol Motil*. 2013 Sep;25(9):776-7.
99. Vaezi MF. Botulinum toxin in nonachalasia motility disorders: a welcomed therapy in an area with limited therapeutic options. *Clin Gastroenterol Hepatol*. 2013 Sep;11(9):1122-4.
100. Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, Ogbeide E, Tran C, Goutte M, Garrett CG, Hagaman D, Vaezi MF. High economic burden of caring for patients with suspected extraesophageal reflux. *Am J Gastroenterol*. 2013 Jun;108(6):905-11.
101. Yuksel ES, Slaughter JC, Mukhtar N, Ochieng M, Sun G, Goutte M, Muddana S, Gaelyn Garrett C, Vaezi MF. An oropharyngeal pH monitoring device to evaluate patients with chronic laryngitis. *Neurogastroenterol Motil*. 2013 May;25(5):e315-23.
102. Vaezi MF. Chronic cough and gastroesophageal reflux disease: how do we establish a causal link? *Chest* 2013; 143: 587-9.
103. Gyawali CP, Bredenoord AJ, Conklin JL, Fox M, Pandolfino JE, Peters JG, Roman S, Staiano A, Vaezi MF. Esophageal high resolution manometry in community practice. *Neurogastroenteorl Motil* 2013; 25:776-7.
104. Kavitt RT, Yuksel ES, Slaughter JC, Garrett CG, hagaman D, Higginbotham T, Vaezi MF. The role of impedance monitoring in patients with extraesophageal symptoms. *Laryngoscope* 2013; 123:2463-8.
105. Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. *Am J Gastroenterol* 2013; 108:1238-49.
106. Jobe BA, Richter JE, Hoppo T, Peters JH, Bell R, Dengler WC, DeVault K, Fass R, Gyawali CP, Kahrilas PJ, Lacy BE, Pandolfino JE, Patti MG, Swanstrom LL, Kurian AA, Vela MF, Vaezi MF, DeMeester TR. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. *J Am Coll Surg* 2013; 217:586-97.

107. Francis DO, Hall E, Dang JH, Vlacich GR, Netterville JL, Vaezi MF. Outcomes of serial dilation for high grade radiation related esophageal strictures in head and neck cancer patients. *Laryngoscope* 2015; 125:856-62.
108. Ates F, Yuksel ES, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, Garrett CG, Francis D, Vaezi MF. Mucosal impedance discriminates GERD from non-GERD. *Gastroenterology* 2015; 148:334-43.
109. Katzka DA, Ravi K, Geno DM, Smyrk TC, Lyer PG, Alexander JA, Mabary JE, Camilleri M, Vaezi MF. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with EoE. *Clin Gastroenterol Hepatol*. 2015; 13: 1242-48.
110. Yachimski P, Maqubool S, Bhat YM, Richter JE, Falk GW, Vaezi MF. Control of acid and duodenogastroesophageal reflux in patients with Barrett's esophagus. *Am J Gastroenterol* 2015; 110:1143-8.
111. Patel DA, Vaezi MF. A spiraling case of persistent dysphagia. Diffuse esophageal spasm. *Gastroenterology* 2015; 149:298-9.
112. Kavitt R, Ates F, Slaughter JC, Higginbotham T, Shephard BD, Sumner E, Vaezi MF. Randomized controlled trial comparing esophageal dilation to no dilation among adults with EoE. *Dis Esophagus* 2016; 29:983-991.
113. Francis DO, Slaughter JC, Ates F, Higginbotham T, Stevens KL, Garrett CG, Vaezi MF. Airway hypersensitivity reflux and phonation contribute to chronic cough. *Clin Gastroenterol Hepatol* 2016; 14:378-84.
114. Vaezi MF, Brill JV, Mills MR, Bernstein BB, Ness RM, Richards WO, Brillstein L, Lebowitz, R, Stople K, Montgomery EA, Patel K. An episode of payment framework for GERD: symptomatic GERD, dysplastic and non-dysplastic Barrett's esophagus and anti reflux surgical and endoscopic interventions. *Gastroenterology* 2016; 150: 1009-18.
115. Vaezi MF, Brill JV, Mills MR, Bernstein BB, Ness RM, Richards WO, Brillstein L, Lebowitz, R, Stople K, Montgomery EA, Patel K. An episode of payment framework for GERD. *Gastroenterology* 2016; 150: 1019-25.
116. Wright MR, Sharda R, Vaezi MF. Unmet needs in treating LPR: where do we go from here? *Expert Rev Gastroenterol Hepatol* 2016; 10:995-1004.
117. Naik RD, Choksi YA, Vaezi MF. Impact of weight loss surgery on esophageal physiology. *Gastroenterol Hepatol* 2015; 11:801-9.
118. Kavitt RT, Hirano I, Vaezi MF. Diagnosis and treatment of eosinophilic esophagitis in adults. *Am J Med* 2016; 129:924-34.

119. Patel DA, harb AH, Vaezi MF. Oropharyngeal reflux monitoring and atypical GERD. *Curr Gastroenterol Rep*. 2016; 18:12.
120. Naik RD, Choksi YA, Vaezi MF. Consequences of bariatric surgery on Oesophageal function in health and disease. *Nat Rev Gastroenterol Hepatol* 2016; 13:111-9.
121. Patti MG, Vela MF, Odell DD, Richter JE, Fisichella PM, Vaezi MF. The intersection of GERD, aspiration and lung transplantation. *J Laparoendosc Adv Surge Tech A*. 2016; 26:501-5.
122. Gurwara S, VaVee T, Vaezi MF. He did not cry wolf: the case of a man with lupus and 10 years of dysphagia. *Gastroenterology* 2016; 151:245-7.
123. Kavitt RT, Lal P, Yuksel ES, Ates F, Slaughter JC, Garrett CG, Higginbotham T, Vaezi MF. Esophageal mucosal impedance pattern is distinct in patients with extraesophageal reflux symptoms and pathologic acid reflux. *J Voice* 2017; 31:347-351.
124. Francis DO, Patel DA, Sharda R, Hovis K, Sathe N, Penso DF, Feurer ID, McPheeters ML, Vaezi MF. *Otolaryngol Head Neck Surg*. 2016; 155:923-35.
125. Pointer SD, Rickstrew J, Slaughter JC, JC, Vaezi MF, Silver HJ. Dietary carbohydrate intake insulin resistance and GERD: a pilot study in European and African American obese women. *Alim Pharmacol Ther*. 2016; 44:976-988.
126. Vaezi MF, Felix VN, Penagini R, Mauro A, de Moura EG, Pu LZ, Marinek J, Rieder E. Achalasia: from diagnosis to management. *Ann N Y Acad Sci* 2016, 1381:34-44.
127. Vaezi MF. Editorial: Reflux and laryngeal symptoms: A sea of confusion. *Am J Gastroenterol* 2016; 111:1525-1527.
128. Krill JT, Naik RD, Higginbotham T, Slaughter JC, Holzman MD, Francis DO, Garrett CG, Vaezi MF. Association between response to acid suppression therapy and efficacy of antireflux surgery in patients with extraesophageal reflux. *Clin Gastroenterol Hepatol*. 2017; 15:675-681.
129. Schneider GT, Vaezi MF, Francis DO. Reflux and voice disorders: have we established causality? *Curr Otorhinolaryngol Rep* 2016; 4:157-67.
130. Vaezi MF, Choksi Y. Mucosal impedance: A new way to diagnose reflux disease and how it could change your practice. *Am J Gastroenterol* 2017; 112; 4-7.
131. Vaezi MF, Yang YX, Howden CW. Complications of PPI therapy. *Gastroenterology* 2017; 153:35-48.

132. Patel DA, Sharda R, Hovis KL, Vaezi MF, et al. Patient reported outcome measures in dysphagia: a systematic review of instrument development and validation. *Dis Esophagus* 2017; 30: 1-23.
133. Dellon ES, Liacouras CA, Molina-Infante J, Vaezi MF. et al. Updated International consensus diagnostic criteria for EoE: Proceedings of the AGREE conference. *Gastroenterology* 2018 155:1022-33.
134. Choksi Y, Vaezi MF. Preliminary esophageal microbiome studies prompt important scientific questions. *Clin Transl Gastroenterol* 2018; 9:156.
135. Patel DA, Naik R, Slaughter JC, Higginbotham T, Silver H, Vaezi MF. Weight loss in achalasia is determined by its phenotype. *Dis Esophagus* 2018; (epub ahead of print).
136. Yadlapati R, Vaezi MF, Vela MF, et al. Management options for patients with GERD and persistent symptoms on PPI's: recommendations from an expert panel. *Am J Gastroenterol* 2018; 113:980-86.
137. Lowry MA, Vaezi MF, Correa H, et al. Mucosal impedance measurements differentiate pediatric patients with active versus inactive EoE. *J Pediatr Gastroenterol Nutr.* 2018; 67:198-203.
138. Hiremath G, Vaezi MF, Gupta SK et al. Management of esophageal food impaction varies among gastroenterologists and affects identification of EoE. *Dig Dis Sci* 2018; 63:1428-37.
139. Choksi Y, Slaughter JC, Sharda R, Higginbotham T, Lal P, Vaezi MF. Symptom association probability does not reliably distinguish functional heartburn from reflux hypersensitivity. *Alim Pharmacol Ther.* 2018; 47:958-65.
140. Choksi Y, Lal P, Slaughter JC, Sharda R, Higginbotham T, Lal P, Vaezi MF. Esophageal mucosal impedance patterns discriminate patients with EoE from GERD. *Clin Gastroenterol Hepatol* 2018; 16:664-71.
141. Patel DA, Krishnaswami S, Steger E, Concover E, Vaezi MF, et al. Economic and survival burden of dysphagia among inpatients in the US. *Dis Esophagus* 2018; 31:1-7.
142. Vaezi MF, Sifrim D. Assessing old and new diagnostic tests for GERD. *Gastroenterology* 2018; 154-289-301.
143. Patel DA, Sharda R, Choksi YA, ...Vaezi MF. Model to select on therapy vs off therapy tests for patients with refractory esophageal or extraesophageal symptoms. *Gastroenterology* 2018; 155:1729-40.
144. Zaninotto G, Bennett C, Boeckxstaens G, ...Vaezi MF. The 2018 ISDE achalasia guidelines. *Dis Esophagus* 2018; 31.

145. Patel D, Vaezi M. Opioid induced esophageal dysfunction: an emerging entity with sweeping consequences. *Curr Treat Options Gastroenterol* 2018; 16:616-21.
146. Patel DA, Higginbotham T, Slaughter JC, Aslam M, Yuksel E, Katzka D, Gyawali CP, Mashi M, Pandolfino J, Vaezi MF. Development and Validation of a mucosal impedance contour analysis system to distinguish esophageal disorders. *Gastroenterology* 2019; 156:1617-1626.
147. Lechien JR, Akst LM, Hamdan AL,..., Vaezi MF. Evaluation and management of LPR: State of art Review. *Otolaryngol Head Neck Surg*. 2019; 160:762-82.
148. Lechien JR, Saussez S, Schindler A, ..Vaezi MF. Clinical outcomes of LPR treatment: A systematic review and meta-analysis. *Laryngoscope* 2019; 129:1174-87.
149. Alexander JA, Ravi K, Geno DM, ...Vaezi MF, Katzka DA. Comparison of mucosal impedance measurements throughout the esophagus and mucosal eosinophil counts in endoscopic biopsy specimens in EoE. *Gastrointest Endosco* 2019; 89:693-700.
150. Wong ME, Blair MJ, Chang WC, ..Vaezi MF, Gyawali CP, Chen CL. Clinical and psychosocial characteristics in GERD patients overlapping with LPR. *J Gastroenterol Hepatol*. 2019; 34:1720-26.
151. Lei WY, Chang WC, ...Vaezi MF et al. Impact of concomitant dyspepsia and irritable bowel syndrome on symptom burden in patients with GERD. *J Formosan Med Ass*. 2019; 118:797-806.
152. Choksi YA, Chaparro J, Blanco M, ...Vaezi MF. Impedance and histologic characteristics of the sub-laryngeal esophagus distinguish EoE from other esophageal disorders. *Clin Gastroenterol Hepatol* 2020; 18:1727-35.
153. Lien HC, Wang CC, Yeh HZ, ...Vaezi MF, Chang CS. Distinct physiological characteristics of isolated laryngopharyngeal reflux symptoms. *Clin Gastroenterol Hepatol* 2020; 18:1466-74.
154. Lei Wy, Vaezi MF, Naik RD, Chen CL. Mucosal impedance testing: a new diagnostic testing in GERD. *J Formos Med Assoc* 2020; 119:1575-80.
155. Patel D, Callaway J, Vaezi MF. Opioid induced foregut dysfunction. *Am J Gastroenterol* 2019; 114:1716-25.
156. Adams DW, Patel D, Evers L, Slaughter JC, Higginbotham T, Vaezi M. Measurement of duodenal mucosal integrity are altered in Celiac disease. *Clin Gastroenterol Hepatol* 2019; Jul 24. Pii:S1542-3565.
157. Naik RD, Vaezi MF. Outcomes data on surgical therapies for silent reflux. *JAMA Otolaryngol Head Neck Surg* 2019; 145:667-668.

158. Gyawali CP, Sifrim D, Carlson DA, ...Vaezi M, Clarke JO, Triadafilopoulos G. Ineffective esophageal motility: concepts, future directions, and conclusions from the Stanford 2018; symposium. *Neurogastroenterol Motil* 2019; 31:e13584.
159. Dellon ES, Peterson KA, ..Vaezi MF. Anti-singlec 8 antibody for eosinophilic gastritis and duodenitis. *N Engl J Med* 2020; 383:1624-1634.
160. Vaezi MF, Fass, R, Vakil N, et al. IW-3718 reduces heartburn severity in patients with refractory GERD in a randozmied trial. *Gastroenterology* 2020; 158:2093-2103.
161. Lei WY, Wang JH, Yi C, ...Vaezi MF, et al. Association between use of proton pump inhibitors and colorectal cancer: a nationwide population-based study. *Clin Res Hepatol Gastroenterol* 2021; 45:101397.
162. Vaezi MF, shaheen NJ, Muthusamy R. State of evidence in minimally invasive management of GERD: findings of a scoping review. *Gastroenterology* 2020; 159:1504-25.
163. Mittal R and Vaezi MF. Esophageal motility disorders and GERD. *N Engl J Med* 2020; 383:1961-72.
164. Yadlapati R, Kahrilas PJ, ...Vaezi MF., et al. Esophageal motility disorders on high resolution manometry: Chicago classification version 4.0 *Neurogastroenterol Motility* 2020; 33:e14058.
165. Zerbib F, Bredenoer AJ...Vaezi MF., et al. ESNM/ANMS consensus paper: diagnosis and management of refractory GERD. *Neurogastroenterol Motility* 2020; 33:e14075.
166. Desai M, Nutalapati V, ..Vaezi MF., et al. Proton pump inhibitors do not increase the risk of dementia: a systematic review and metal analysis of prospective studies. *Dis Esoph* 2020; 33:1-9.
167. Kamal AN, Kathpalia P,...Vaezi MF., et al. Development of quality indicators for the diagnosis and management of achalasia. *Neurogastroenterol Motility* 2021; 33:e14118.
168. Vaezi MF, Pandolfino J, Yadlapati R. et al. ACG clinical guidelines: diagnosis and management of achalasia. *Am J Gastroenterol* 2020; 115:1393-1411.
169. Patel D and Vaezi M. Bringing real-time live feedback to esophageal dilations, but not ready for prime time. *Gastrointestinal Endoscopy*, 2020 Dec; 92 (6): 1258-1260.
170. Basil M, Schwartz D, ..Vaezi MF et al. Mucosal integrity testing can detect differences in the rectum of patients with IBD compared to controls: a pilot study. *Dig Dis Sci* 2021; Feb.

171. Naik R, Gershon A, Higginbotham T, Chen J, Flores E, Holzman M, Patel D, Vaezi M, and Gershon M. Association of Achalasia with Active Varicella Zoster Virus Infection of the Esophagus. *Gastroenterology*, Feb 2021, accepted, pending publication

#### INVITED PUBLICATIONS:

1. Vaezi, M.F. and Richter, J.E.: Managing gastroesophageal reflux disease in elderly patients. *Clinical Geriatrics*, 1994; 2:11-29.
2. Vaezi, M.F., Richter, J.E. Importance of bile reflux in Barrett's esophagus. *Practical Gastroenterology*; 1995; 19 (8):52B-52J.
3. Vaezi, M.F., Richter, J.E. An ambulatory bilirubin monitoring device for duodenogastroesophageal reflux. in *Surgical Technology International* volume V, Eds. Szabo Z., Universal Medical Press, San Francisco; 1996, pp 125-130.
4. Vaezi, M.F., Richter, J.E. Gastroesophageal reflux disease. *Current Opinion Gastroenterol* 1997; 13:327-332.
5. Vaezi, M.F., Richter, J.E. Gastroesophageal reflux disease: diagnosis, treatment and complications. *Sleisenger and Fordtran 1997 update series*; 27:21-35.
6. Vaezi, M.F. Duodenogastroesophageal reflux-alias "alkaline" or "bile" reflux. in *ambulatory esophageal pH monitoring-practical approach and clinical applications*, Ed. Richter JE. Williams and Wilkins, NY; 1997, pp 207-224.
7. Vaezi, M.F., Richter, J.E. Bile reflux in columnar-lined esophagus. *Gastroenterol Clin N Am* 1997; 26:565-582.
8. Vaezi, M.F., Richter, J.E. Current therapies for achalasia. *J. Clin Gastroenterol* 1998; 27:21-35.
9. Vaezi, M.F. Duodenogastroesophageal reflux; in *The esophagus*, Ed. Castell, Donald D. Lippincott Raven, NY; 1999, pp 421-436.
10. Vaezi, M.F., Richter, J.E. Importance of duodenogastroesophageal reflux in the medical outpatient practice. *Hepatogastroenterology* 1999; 46:40-47.
11. Vaezi, M.F. Achalasia: Diagnosis and Management. *Sem Gastrointest diseases* 1999; 10:103-112.
12. Vaezi, M.F., Richter, J.E. Practice guideline for the diagnosis and management of Achalasia. *Am J Gastroenterol* 1999, 94:3406-3412.

13. Vaezi, M.F. Pathophysiology of GERD: Are duodenal contents important? Practical Gastroenterol; 2000, 14-24.
14. Vaezi, M.F., Richter, J.E. Duodenogastroesophageal reflux. Bailliere's Clinical Gastroenterology 2000; 14, 719-729.
15. Vaezi, M.F. Quantitative methods to determine efficacy of treatment in achalasia. Gastrointest Endo Clin N Am. 2001; 11:409-424.
16. Vaezi, M.F., Richter, J.E. Importance of bile reflux in Barrett's esophagus; in Barrett's esophagus and esophageal adenocarcinoma; Sharma and Sampliner, Eds. 2001; PP24-34.
17. Vaezi, M.F., Shay, S.S. New techniques in measuring non-acidic esophageal reflux. Seminar Thorac Cardiovasc Surg 2001; 13:255-64.
18. Vaezi, M.F., Richter, J.E. Duodeogastroesophageal reflux and methods to monitor non-acidic reflux. Am J Med 2001; 111:S160-S168.
19. Vaezi, M.F. ENT Manifestations of GERD. Clinical Perspective in Gastroenterology 2002; 5:324-8.
20. Vaezi, M.F.. Duodenogastroesophageal reflux; in the esophagus, Ed. Castell, Donald and Richter Joel. D. Lippincott Raven, NY; 2003, 421-436.
21. Vaezi, M.F. Sensitivity and specificity of reflux attributed laryngeal lesions: Experimental and Clinical Evidence. Am J Med. 2003; 115:97-104.
22. Vaezi, M.F. Gastroesophageal reflux disease and the larynx. J Clin Gastroenterol 2003; 36:198-203.
23. Vela, M.F., Vaezi, M.F. Pathophysiology of GERD; in GERD/Dyspepsia. Ed. Fass, Ronnie; Hanley and Belfus, PA, 2004, pp. 23-40.
24. Vaezi, M.F. The Esophagus; in MKSAP 13; The American College of Physicians; 2003.
25. Vela, M. F., Vaezi, M.F.. Cost-assessment of alternative management strategies for achalasia. Expert Opin Pharmacother 2003; 4:2019-25.
26. Vaezi, M.F. Ear, nose and throat manifestations of gastroesophageal reflux disease. GI Frontiers, 2003; 1:3-4.
27. Vaezi, M.F. Ear, nose and throat manifestations of gastroesophageal reflux disease. Clin Perspec Gastroenterol 2003; Nov/Dec.: 1-5.
28. Vela, M.F., Vaezi, M.F. Cost-assessment of alternative management strategies for achalasia. Expert Opin Pharmacother. 2003; 4:2019-25.



29. Vaezi, M.F. Extraesophageal manifestations of gastroesophageal reflux disease. *Clinical Cornerstones* 2004; 5:32-8.
30. Vaezi, M.F. Laryngitis and GERD: improve laryngoscopic specificity, don't do pH monitoring. *Dig. Liver Dis.* 2004, 36:103-105.
31. Nayar, D., Vaezi, M.F. Classifications of esophagitis: who needs them? *Gastrointest Endosc.* 2004; 60:253-7.
32. Vaezi, M.F. Duodenogastroesophageal reflux; in *The esophagus*, Eds. Castell, Donald; Richter Joel. D.Lippincott Raven, NY; 2004, pp 434-450.
33. Ahmed, T., Vaezi, M.F. Twenty four hour pH monitoring in extraesophageal disease. *Gastrointest Clin. N Am.* 2005; 15:319-31.
34. Park, W., Vaezi, M.F. Esophageal impedance recording: Clinical Utility and Limitations. *Curr Gastroenterol Rep* 2005; 7:182-9.
35. Vela, M.F., Vaezi, M.F. Advances in gastro-oesophageal reflux disease. In *The Year in Gastroenterology and Hepatology*; Vol 1. 2005; pp. 39-52.
36. Vaezi, M.F. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD). *Nature Clinical Practice:Gastroenterology and Hepatology.* 2005; 2:595-603.
37. Vaezi, M.F. Extraesophageal manifestation of gastroesophageal reflux disease. *Business Briefing: US Gastroenterology Review* 2005:36-39.
38. Maqbool, S., Vaezi, M.F. Gastroesophageal reflux disease (GERD) in *Conn's Current Therapy*; 59<sup>th</sup> edition. 2005.
39. Vaezi, M.F. Therapy Insight: Gastroesophageal reflux disease and laryngopharyngeal reflux. *Gastroenterol Hepatol.* 2005;2: 595-603.
40. Vollweiller, J.F., Vaezi, M.F. The esophagus; in *Otolaryngology of the Head and Neck*, 4<sup>th</sup> edition, Ed Charles W. Cummings Jr. Elsevier 2006, pp.1835-1876.
41. Vaezi, M.F. What is the optimal treatment for patients with ENT symptoms related to DGER? in *Duodenogastroesophageal reflux*; editor R. Giuli, 2006-pp. 279-281.
42. Vaezi, M.F. Limitations in detecting bile reflux in vivo in Duodenogastroesophageal reflux; editor R. Giuli, 2006; pp. 32-36.
43. Vaezi, M.F. Can DGER be quantitatively measured in man? in *Duodenogastroesophageal reflux*; editor R. Giuli, 2006; pp. 73-76.

44. Vaezi, M.F. Is the term alkaline reflux a misnomer? in Duodenogastroesophageal reflux; editor R. Giuli, 2006; pp 64-65.
45. Vaezi, M.F. What is the value of multichannel intraluminal impedance monitoring in the assessment of non-acid GER? in Duodenogastroesophageal reflux; editor R. Giuli, 2006; pp.123-128.
46. Vaezi, M.F., Swoger, J. GERD in the elderly; in Gastroesophageal reflux disease Eds Granderath, Kamolz, Poitner; Springer Wien, New York 2006; 23-44.
47. Vaezi, M.F. Treatment of chronic throat symptoms with PPI's should not be preceded by pH monitoring. *Am J Gastroenterol.* 2006 Jan; 101(1):8-10.
48. Vaezi, M.F. Atypical manifestations of gastroesophageal reflux disease *MedGenMed.* 2005 Oct 27; 7(4):25.
49. Vaezi, M.F. Review article: the role of pH monitoring in extraesophageal gastro-oesophageal reflux disease. *Aliment Pharmacol Ther.* 2006 Mar;23 Suppl 1:40-9.
50. Vaezi, M.F. Reflux-induced laryngitis (laryngopharyngeal reflux). *Curr Treat Options Gastroenterol.* 2006 Feb;9(1):69-74.
51. Vaezi, M.F. Esophageal Diseases: an atlas of investigation and management. ed. Michael Vaezi. 2006; Clinical Publishing.
52. Vaezi, M.F. Esophageal function testing-the old and the new. *Alimen Pharm Therap.* 2007; 3:1-13.
53. Farrokhi, F., Vaezi, M.F. Extra-esophageal manifestations of gastroesophageal reflux. *Oral Dis.* 2007 Jul; 13 (4): 349-59.
54. Farrokhi, F., Vaezi, M.F. Idiopathic (primary) achalasia. *Orphanet J. Rare Dis.* 2007 Sept 26; 2-38.
55. Vaezi M.F. Sore throat and red hypopharynx. Is it reflux? *Clin Gastroenterol Hepatol.* 2007;5:1379-82
56. Qadeer, M.A., Vaezi M.F. Esophageal Motility Disorders in *Pearson's Thoracic and Esophageal Surgery* (Editors: Patterson GA et al) 2008, 3<sup>rd</sup> Ed, Vol 2: 714-724.
57. Vaezi M.F. GERD and obesity: a real BIG issue. *Gastroenterology* 2008; 134:882-3.
58. Vaezi M.F. Laryngeal manifestations of GERD. *Curr Gastroenterol Rep* 2008; 10 (3): 271-7.

59. Frye, J.W., Vaezi, M.F. Extraesophageal GERD. *Gastroenterol Clin North Am.* 2008; 37 (4): 845-58.
60. Vaezi M.F. ENT Manifestations of GERD: The Gastroenterologist's Perspective. *Gastroenterology and Hepatology* 2009; 5:395-396.
61. Hong, S.K., Vaezi, M.F. Gastroesophageal reflux monitoring: pH (catheter and capsule) and impedance. *Gastrointest Endosc Clin N. Am.* 2009 Jan; 19 (1): 1-22.
62. Barry D.W., Vaezi, M.F. Laryngopharyngeal reflux: More questions than answers. *Cleve. Clin. J. Med.* 2010; 77:327-34.
63. Oranu A.C. Vaezi, M.F. Non-cardiac chest pain: gastroesophageal reflux disease. *Med. Clin. North Am.* 2010; 94:233-42.
64. Moore JM, Vaezi MF. Extraesophageal manifestation of gastroesophageal reflux disease; real or imagined? *Curr Opin Gastroenterol* 2010; 26:389-94.
65. Vaezi MF. Gastroesophageal reflux related chronic laryngitis: Con. *Arch Otolaryngol Head Neck Surg.* 2010; 136:908-9.
66. Kamal A, Vaezi MF. Diagnosis and initial management of gastroesophageal complications. *Best Pract Res Clin Gastroenterol* 2010; 24: 799-820.
67. Vaezi MF. Reflux monitoring: on or off therapy? *Am J Gastroenterol* 2011; 106:183-185.
68. Abou-Ismaïl A, Vaezi MF. Evaluation of patients with suspected laryngopharyngeal reflux: a practical approach. *Curr Gastroenterol Rep.* 2011; 13:213-8.
69. Vaezi MF. Safety of proton pump inhibitors. *Gastroenterol and Hepatol* 2011;7:10-12.
70. Saritas Y, Vaezi MF. Extraesophageal manifestation of GERD: cough, asthma, laryngitis and chest pain. *Swiss Med Wkly,* 2012; 142.
71. Vaezi MF. Use of symptom indices in the management of GERD. *Gastroenterol Hepatol.* 2012; 8:185-187.
72. Saritas Yuksel E, Vaezi MF. New developments in extraesophageal reflux disease. *Gastroenterol Hepatol* 2012; 8:590-9.
73. Yuksel ES, Vaezi MF. Therapeutic strategies for laryngeal manifestations of gastroesophageal reflux disease. *J Clin Gastroenterol* 2013.
74. Vaezi MF. New tests for the evaluation of LPR. *Gastroenterol Hepatol.* 2013; 9:115-7.

75. Hom C, Vaezi MF. Extraesophageal manifestations of GERD: diagnosis and treatment. *Drugs* 2013; 73:1281-95.
76. Hom C, Vaezi MF. Extraesophageal GERD. *Gastroenterol Clin North Am* 2013; 42:71-91.
77. Naik RD; Vaezi MF. Extraesophageal GERD: who responds to therapy? *Curr Gastroenterol Rep.* 2013; 15:318-324.
78. Vaezi MF. Botulinum toxin in nonachalasia motility disorders: a welcomed therapy in an area with limited therapeutic options. *Clin Gastroenterol Hepatol* 2013; 11:1122-4.
79. Hom C, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: diagnosis and treatment. *Drugs* 2013; 73:1281-95.
80. Vaezi MF, Kahrilas PJ. Barrett's esophagus surveillance: time to rethink if one size fits all? *Gastroenterology* 2013; 145:503-5.
81. Vaezi MF. New tests for the evaluation of LPR. *Gastroenterol Hepatol* 2013; 9:115-7.
82. Ates F, Vaezi MF. Approach to the patient with presumed extraesophageal GERD. *Best Pract Res Clin Gastroenterol* 2013;27:415-31.
83. Vaezi MF. The ACG guidelines on achalasia: what clinicians need to know. *Curr Gastroenterol Rep.* 2013; 15:358.
84. Patel D, Vaezi MF. Normal esophageal physiology and laryngopharyngeal reflux. *Otolaryngol Clin North Am* 2013; 46:1023-41.
85. Ates F, Vaezi MF. New approaches to management of PPI refractory gastroesophageal reflux disease. *Curr Treat Options Gastroenterol* 2014: 12:18-33.
86. Ates F, Francis DO, Vaezi MF. Refractory GERD: advances and treatment. *Expert Rev Gastroenterol Hepatol* 2014; in press.
87. Aslam M, Vaezi MF. Dysphagia in the elderly. *Gastroenterol Hepatol* 2013: 9:784-95.
88. Francis DO, Vaezi MF. Should the reflex be reflux? Throat symptoms and alternative explanations. *Clin Gastroenterol Hepatol* 2015; 13:1560-6.
89. Vaezi MF. Ambulatory monitoring for GERD: where do we stand? *Clin Gastroenterol Hepatol* 2015; 13:892-4.
90. Naik RD, Vaezi MF. Extraesophageal GERD and asthma: understanding this interplay. *Expert Rev Gastroenterol Hepatol* 2015; 9:969-82.

91. Ates F, Vaezi MF. The pathogenesis and management of achalasia: current status and future directions. *Gut Liver* 2015; 9:449-63.
92. Patel D, Kim HP, Zifodya JS, Vaezi MF. Idiopathic achalasia: a review. *Orphanet J Rare Dis* 2015, Jul 22; 10:89.
93. Naik RD, Choksi YA, Vaezi MF. Impact of weight loss surgery on esophageal physiology. *Gastroenterol Hepatol* 2015; 11:801-9.
94. Naik RD, Choksi YA, Vaezi MF. Consequences of bariatric surgery on esophageal function in health and disease. *Nat Rev Gastroenterol Hepatol* 2015; *Nat Rev Gastroenterol Hepatol* 2016; 13:111-9.
95. Patel DA, Harb AH, Vaezi MF. Oropharyngeal reflux monitoring and atypical GERD. *Curr Gastroenterol Rep.* 2016; 18:12.
96. Krill JT, Naik RD, Vaezi MF. Clinical management of achalasia: current state of the art. *Clin Exp Gastroenterol* 2016; 9:71-82.
97. Wright MR, Sharda R, Vaezi MF. Unmet needs in treating LPR: where do we go from here? *Expert Rev Gastroenterol Hepatol* 2016; 10:995-1004.
98. Vaezi MF. Diagnosing GERD with endoscopic guided MI. *Gastroenterol Hepatol* 2016; 12:266-8.
99. Vaezi MF. Reflux and laryngeal symptoms: A sea of confusion. *Am J Gastroenterol* 2016; 111:1525-27.
100. Naik RD, Vaezi MF. Recent advances in diagnostic testing for gastroesophageal reflux disease. *Expert Rev Gastroenterol Hepatol* 2017; 11:531-37.
101. Vaezi MF. Does my patient still have reflux when PPI therapy does not work? *Neurogastroenterol Motil* 2017; 29:5.
102. Patel DA, Vaezi MF. Utility of esophageal mucosal impedance as a diagnostic test for GERD. *Curr Opin Gastroenterol* 2017; 33:277-84.
103. Patel DA, Vaezi MF. Refractory Achalasia: is POEM changing the paradigm? *Clin Gastroenterol Hepatol* 2017; 15:1504-6.
104. Patel DA, Gibson WE, Vaezi MF. Achalasia: its not all about the LES. *Gastroenterology* 2017; 153:e12-e13.
105. Patel DA, Lappas BM, Vaezi MF. An overview of achalasia and its subtypes. *Gastroenterol Hepatol* 2017; 13:411-21.

106. Kavitt RT, Vaezi MF. Concise Commentary: breathing new life into anti-secretory medications. *Dig Dis Sci* 2018; 63:411.
107. Callaway JP, Vaezi MF. Hiatal and Paraesophageal hernias. *Clin Gastroenterol Hepatol* 2018; 16:810-13.
108. Barrett C, Choksi Y, Vaezi MF. MI: A new approach to diagnosing GERD and EoE. *Curr Gastroenterol Rev* 2018; 20:33.
109. Patel DA, Blanco M, Vaezi MF. LPR and functional laryngeal disorder; Perspective and common practice of the general gastroenterologist. *Gastroenterol Hepatol* 2018; 14:512-20.
110. Naik RD, Evers L, Vaezi MF. Advances in the diagnosis and treatment of GERD: New tricks for an old disease. *Curr Treat Options Gastroenterol* 2019; 17: 1-17.
111. Naik RD, Vaezi MF. Editorial: breaking the cycle of cough in GERD neuromodulators to the rescue? *Aliment Pharmacol Ther* 2019; 49:1242-43.
112. Barrett CM, Patel D, Vaezi MF. LPR and atypical GERD. *Gastrointest Endosc Clin* 2020; 30:361-76.
113. Patel D, Fass R, Vaezi M. Untangling non-erosive reflux disease from functional heartburn. *Clin Gastroenterol Hepatol* 2020; S1542-65.
114. Richter J, Vaezi MF. An alternative recommendation by experienced esophagologists. *Am J Gastroenterol* 2021; 116:214.

#### **BOOKS EDITED:**

1. Vaezi MF. Esophageal diseases: An atlas of investigation and management. Clinical Publishing 2006.
2. Vaezi MF. Extraesophageal reflux. Plural Publishing 2009
3. Vaezi MF. Diagnosis and treatment of gastroesophageal reflux disease. Springer 2016.
4. Patel D, Kavitt R, Vaezi MF. Evaluation and management of dysphagia. Springer 2020.

#### **PRESENTATIONS/ ABSTRACTS:**

1. Vaezi, M.F., Hope, K.D., Brouillette, W.J., Muccio, D.D. Synthesis and Spectroscopy of C-13 Labeled 3, 4-Dehydroretinoids. ACS Southeastern Regional Meeting, Raleigh, N.C., October 24-26, 1984 (Poster).
2. Vaezi, M.F., Brouillette, W.J., Muccio, D.D. Synthesis and Absorption Properties of Some Conformationally Restricted Retinoids about the 6-7 Bond. The annual Sigma Xi Research Day, 1988, 1987, and 1986 (Oral Presentations).

3. Vaezi, M.F., Brouillette, W.J., Muccio, D.D. Synthesis and Absorption Properties of Some Conformationally Restricted Retinoids about the 6-7 Bond. ACS National Meeting, Toronto, Canada, June 5-10, 1988 (Oral Presentation).
4. Vaezi, M.F., Brouillette, W.J., Muccio, D.D. <sup>13</sup>C NMR Chemical Shift Assignments of Conformationally Restricted 6-s-trans Retinoids. Southeastern Magnetic Resonance Conference, October 29-30, 1993 (Poster).
5. Vaezi, M.F. Transient Protein S Deficiency in a Patient with Acute Ulcerative Colitis, American College of Physicians Annual Meeting, clinical vignette presentation, June, 1993 (Oral Presentation).
6. Vaezi, M.F. Whipple's disease. American College of Physicians Annual Meeting, clinical vignette presentation, June, 1996 (Oral Presentation).
7. Vaezi, M.F., LaCamera, R.G., Richter, J.E. Bilitec: How Well Does it Measure Duodenogastroesophageal (DGE) Reflux? Gastroenterology 1994; 106:A201; Annual Meeting of the AGA, May 15-18, 1994 (Poster).
8. Vaezi, M.F., Champion, G.L., Richter, J.E. Role of Duodeno-gastroesophageal Reflux (DGER) and Bile Acids in Development of Barrett's Esophagus. Gastroenterology 1994; 106:A201; Annual Meeting of the AGA, May 15-18, 1994 (Oral presentation).
9. Schroeder, P.L., Vaezi, M.F., Richter, J.E. Reproducibility of proximal and distal esophageal pH Monitoring. Am. J. Gastroenterol. 1994; 89:1627 (A48); Annual Meeting of the ACG, September 28-29 1994 (Poster).
10. Vaezi, M.F., Richter, J.E. 24-Hour pH monitoring in the diagnosis of cough due to gastroesophageal reflux disease (GERD). Am. J. Gastroenterol. 1994; 89:1630 (A61); Annual Meeting of the ACG, September 28-29 1994 (Poster).
11. Vaezi, M.F., Richter, J.E. Complicated Barrett's esophagus: Role of acid and bile. Am. J. Gastroenterol. 1994; 89:1630 (A62); Annual Meeting of the ACG, September 28-29 1994 (Oral presentation).
12. Schroeder, P.L., Vaezi, M.F., Richter, J.E. Barium vs nuclear scintigraphy: which is better for evaluating patients with achalasia? Gastroenterology 1995; 108:A215; Annual Meeting of the AGA, May 14-17, 1995 (Oral presentation).
13. Vaezi, M.F., Richter, J.E. Role of acid and bile in gastroesophageal reflux disease. Gastroenterology 1995; 108:A249; Annual Meeting of the AGA, May 14-17, 1995 (poster).
14. Vaezi, M.F., Sears, R., Richter, J.E. Double-blind placebo controlled cross-over trial of cisapride in postgastrectomy patients with duodenogastric reflux (DGR). Gastroenterology 1995; 108:A249; Annual Meeting of the AGA, May 14-17, 1995 (poster).

15. Vaezi, M.F., Richter, J.E. Predictive parameters for Barrett's esophagus: a study using prolonged pH and bilirubin monitoring. *Am. J. Gastroenterol.* 1995; 90:1573 (A81); Annual Meeting of the ACG, September 28-29 1995 (poster).
16. Vaezi, M.F., Richter, J.E. Acid and duodenogastroesophageal reflux (DGER) in postgastrectomy (PG) patients: response to therapy. *Am. J. Gastroenterol.* 1995; 90:1573 (A80); Annual Meeting of the ACG, September 28-29 1995 (oral).
17. Vaezi, M.F., Richter, J.E., Wilcox, M., Schroeder, P.L., Slaughter, R.L. One year follow-up: pneumatic dilation more effective than botulinum toxin. *Gastroenterol* 1997; 112:A318; Annual Meeting of the AGA, May 10-16, 1997 (oral).
18. Vaezi, M.F., Baker, M.E., Richter, J.E. Outcome predictors in achalasia patients post-pneumatic dilation and botulinum toxin. *Am. J. Gastroenterol.* 1997; 92: 1605 (A89); Annual Meeting of the ACG, November 1-5, 1997 (oral).
19. Vicari, J.J., Falk, G.W., Vaezi, M.F., Goldblum, J.R., Rice, T.W., Perez-Perez, G.I., O'Connor, J.B., Blaser, M.J., Richter, J.E. Cag A positivity may be protective against more severe grades of esophagitis. *Gastroenterol* 1998; 114:G1325; Annual Meeting of the AGA, May 16-22, 1998.
20. Peek, R.M., Vaezi, M.F., Vicari, J.J., Falk, G.W., Goldblum, J.R., Rice, T.W., Perez-Perez, G.I., O'Connor, J.B., Blaser, M.J., Richter, J.E. Seropositivity to cagA, hspA, and IgA identifies *Helicobacter pylori* strains that induce pre-malignant changes in the gastric cardia but not in the esophagus. *Gastroenterol* 1998; 114:G2727; Annual Meeting of the AGA, May 16-22, 1998 (poster).
21. Imperiale, T.F., O'Connor, J.B., Vaezi, M.F., Richter, J.E. A cost analysis of alternative treatment strategies for achalasia. *Gastroenterol* 1998; 114:G0076; Annual Meeting of the AGA, May 16-22, 1998 (oral).
22. Vaezi, M.F., Baker, M.E., Richter, J.E. Symptom assessment alone is not sufficient to assess the outcome of pneumatic dilation in achalasia. *Gastroenterol* 1998; 114:G1294; Annual Meeting of the AGA, May 16-22, 1998 (poster).
23. Vaezi, M.F., Vicari, J.J., Falk, G.W., Peek, R.M., Goldblum, J.R., Rice, T.W., Perez-Perez, G.I., O'Connor, J.B., Blaser, M.J., Richter, J.E. CagA+ *H. pylori* colonization may prevent Barrett's esophagus. *Gastroenterol* 1998; 114:G1293; Annual Meeting of the AGA, May 16-22, 1998 (oral).
24. Kiwi, M.D., Vaezi, M.F., Younossi, Z., Singer, M.E. Treatment of symptomatic hydrothorax: a cost effectiveness analysis. *Am. J. Gastroenterol.* 1998; 93: 1760 (A603); Annual Meeting of the ACG, October 12-14, 1998 (poster).



25. Vaezi, M.F., Ormsby, A.H., Gramlich, T.L., Falk, G.W., Goldblum, J.R., Richter, J.E. Cytokeratin stains to distinguish short-segment Barrett's esophagus from intestinal metaplasia (IM) of the esophagogastric junction (EGJ). *Gastroenterology* 1999; Annual Meeting of the AGA, May 1999 (oral).
26. Vaezi, M.F., Ours, T.M., Hicks, D.M., Achkar, E., Richter, J.E. Laryngoscopic signs of gastroesophageal reflux disease: science or fiction? *AJG* 94:2601, 1999.
27. Vaezi, M.F., Achkar, E., Richter, J.E. Rigiflex pneumatic dilation with the 3.0 cm balloon is not an adequate initial treatment for young achalasia patients. *AJG* 94:2601, 1999.
28. Vaezi, M.F., Achkar, E., Richter, J.E. Good esophageal emptying combined with symptom relief predicts long-term success from pneumatic dilation in achalasia. *Gastroenterology* 2000; 118:A1436.
29. Vaezi, M.F., Hicks, D.M., Ours, T.M., Achkar, E., Richter, J.E. Are there specific laryngeal signs for gastroesophageal reflux disease? *Gastroenterology* 2000; 118: A2639
30. Fackler, W.K., Vaezi, M.F., Richter, J.E. Ambulatory gastric pH monitoring-proper probe placement and normal values. *Gastroenterology* 2000; 118: A2597.
31. Fackler, W.K., Vaezi, M.F., Ours, T.M., Richter, J.E. Nocturnal acid breakthrough cannot be eliminated in patients with atypical gastroesophageal reflux disease. *Gastroenterology* 2000, 118: A324.
32. O'Connor, J.B., Mendel E. Singer, Imperiale, T.F., Vaezi, M.F., Richter, J.E. Cost-effectiveness analysis of alternative treatment strategies for achalasia. *Gastroenterology* 2000; 118: A1314.
33. Fackler, W.K., Vaezi, M.F., Ours, T.M., Richter, J.E. Nocturnal acid breakthrough and H2Ras-another viewpoint. *Am J Gastroenterol* 2000; 95:A30.
34. Ours, T.M., Fackler, W.K., Richter, J.E., Vaezi, M.F. H2-receptor antagonists not superior to proton pump inhibitors for nocturnal acid suppression: A prospective study. *Am J Gastroenterol* 2000; 95: A64.
35. Fackler, W.K., Ours, T.M., Vaezi, M.F., Richter, J.E. H2RA's do not provide sustained suppression of nocturnal acid breakthrough. *Gastroenterology* 2001; 120:A172.
36. Ours, T.M., Fackler, W.K., Richter, J.E., Vaezi, M.F. Why are we still prescribing H2-receptor antagonists for nocturnal acid suppression? *Gastroenterology* 2001; 120: A173.
37. Vaezi, M.F., Hicks, D.M., Ours, T.M., Richter, J.E. ENT manifestation of GERD: A large prospective study assessing treatment outcome and predictors of response. *Gastroenterology* 2001; 120:A636.

38. Goldblum, J.R., Richter, J.E., Vaezi, M.F., Falk, G.W., Rice, T.W., Peek, R.M. Helicobacter Pylori infection, not gastroesophageal reflux is the major cause of inflammation and intestinal metaplasia of the native gastric cardia. Gastroenterology. 2001; 120:A2106.
39. Falk, G.W., Ours, T.M., Easley, E., Richter, J.E., Vaezi, M.F., Conwell, D.L., Vargo, J.J., Achkar, E. Can a simple questionnaire enhance endoscopic screening for Barrett's esophagus? Gastroenterology 2001; 120:A2115.
40. Potter, J.W., Vaezi, M.F. Dysphagia: is endoscopy for everyone too costly? Gastroenterology 2001; 120:A3925.
41. Bhat, Y.M., Fackler, W.K., Richter, J.E., Vaezi, M.F. Does classical testing for GERD in patients with atypical symptoms predict response to therapy? Am J Gastroenterol. 2001; 96:A12.
42. Nayar, D.S., Vaezi, M.F. Esophageal manometry: blinded and randomized assessment of interpreter consistency. Am J Gastroenterol. 2001; 96:A76.
43. Ours, T.M., Fackler, W.K., Richter, J.E., Vaezi, M.F. Esophageal pH and reflux symptom response to various treatment regimens: Clinical relevance of nocturnal acid breakthrough. Am J Gastroenterol 2001; 96: A83.
44. Ours T.M., Falk G.W., Richter J.E., Vaezi M.F. Can we normalize esophageal acid and bile exposure in patients with Barrett's esophagus using proton pump inhibitors? Am J Gastroenterology 2002; 97:A66.
45. Farhoomand, K, Richter, J.E., Achkar, E, Connor, J.T, Vaezi, M.F. A new predictor of outcome of pneumatic dilation in achalasia Gastroenterology 2003; 124: S1626.
46. Vaezi M.F., Hicks, D.M., Abelson, T.I., Richter, J.E. A large scale study in search of more specific laryngeal signs for GERD. Gastroenterology 2003; 124: A579.
47. Richter, J.E., Vaezi, M.F., Stasney, R., Hwang, C., Leathers, T., Sostek, M., Shaker, R. Baseline pH measurements of patients with suspected signs and symptoms of reflux laryngitis. Gastroenterology 2004; 126:A537.
48. Vaezi, M.F., Richter, J.E., Stasney, R., Spiegel, J., Hwang, C., Leathers, T., Sostek, M., Shaker, R. A randomized double blind, placebo-controlled study of acid suppression for the treatment of suspected LPR. Gastroenterology 2004, 126:A22.
49. Vaezi, M.F., Richter, J.E., Stasney, R., Ianuzzi, R., Hwang, C., Leaters, T., Sostek, M. The safety and tolerability of double dose esomeprazole (40mg twice daily). Gastroenterology 2004; 126:A22.

50. Swoger, J., Khandwala, F., Hicks, D.M., Richter, J.E., Vaezi, M.F. Long-term follow-up of patients with acid suppressive therapy for suspected reflux related laryngeal signs and symptoms. *Gastroenterology* 2004; 126:A326.
51. Charbel, S.C., Vaezi, M.F. On-therapy pH monitoring-usually recommended but should we do it? *Gastroenterology* 2004; 126:A82.
52. Khatemi, S., Khandwala, F., Shay, S., Vaezi, M.F. Does DES progress to achalasia? A prospective cohort study over 10 yrs. *Am J Gastroenterol* 2004; 99:A16.
53. Maqbool, S., Bhat, Y., Khandwala, F., Vaezi, M.F. Barrett's esophagus: How much acid suppression is enough? Predictors of response to high dose proton pump inhibitors. *Am J Gastroenterol* 2004; 99:A28.
54. Qadeer, M., Colabianchi, N., Vaezi, M.F. Is GERD a risk factor for laryngeal cancer? A meta analysis. *Am J Gastroenterol* 2004; 99:A26.
55. Park, W., Hicks, D.M., Abelson, T.I., Milstein, C., Richter, J.E., Vaezi, M.F. Is twice daily PPI better than once a day PPI for the treatment of GERD related ENT symptoms? *Am J Gastroenterol* 2004; 99:A78.
56. Ahmed, T., Vaezi, M.F. Chronic Laryngitis Associated with GERD: A Large Scale Prospective Assessment of Differences in Practice Patterns Between Gastroenterologists and ENT Physicians. *Gastroenterology* 2005; 128:M1769.
57. Park, W., Vaezi, M.F. Is reflux laryngitis refractory to high dose PPI therapy caused by persistent acid or non-acid reflux? *Gastroenterology* 2005; 128:M1778.
58. Qadeer, M., Vaezi, M.F. The role of anti-reflux therapy in laryngeal cancer recurrence. *Gastroenterology* 2005; 128:M1780.
59. Swoger, J., Milstein, C., Hicks, D.M., Abelson, T.I., Ponsky, J., Vaezi, M.F. The role of surgical fundoplication in patients unresponsive to aggressive acid suppression. *Gastroenterology* 2005; 128:A630.
60. Qadeer, M., Vaezi, M.F. The role of GERD in laryngeal cancer pathogenesis. *Gastroenterology* 2005; 128:M1779.
61. Maqbool, S., Park, W., Shay, S., Vaezi, M.F. Role of impedance monitoring in patients with typical and atypical reflux symptoms. *Am J Gastroenterol* 2005; Oral presentation
62. Vaezi, M.F., Lopez, R., Hicks, D.M., Abelson, T.I., Milstein, C. What is the optimal initial therapy duration for patients with suspected GERD-related laryngitis? *Gastroenterology* 2006; 130:914 (A-140).

63. Qadeer, M.A., Phillips, C.O., Lopez, A. R., Steward, D.L., Noordzij, J.P., Wo, J.M., Suurna, M., Havas, T., Howden, C.W., Vaezi, M.F. Proton pump inhibitor therapy for suspected GERD-related laryngitis: a meta analysis of randomized controlled trials. *Gastroenterology* 2006; 130:S1187 (A-172).
64. Park, W., Vargo, J.J., Achkar, E., Falk, G.W., Vaezi, M.F. Does endoscopic ultrasound help predict clinical outcome of pneumatic dilation for achalasia? *Gastroenterology* 2006; 130:T1936 (A-577).
65. El-Hachem, S., Lopez, A.R., Rice, T., Vaezi, M.F. Impact of age and gender on success of pneumatic dilation and Heller myotomy in achalasia. *Gastroenterology* 2006; 130:T1938 (A-577).
66. Gilles, M.D., Ayers, G.D., Vaezi, M.F. 96 hours no better than 24 hours in atypical GERD. *Gastroenterology* 2007; 132: 693 (A-99).
67. Vaezi, M.F., Qadeer, M.A., Hicks, D.M. In the larynx, what is red is not GERD. *Gastroenterology* 2007; 132: T1178 (A-483).
68. Pritchett, J.M., Slaughter, J.C., Vaezi, M.F. Is esophageal impedance monitoring detecting something new? A case-control study assessing predictive nature of non-acid reflux. *Gastroenterology* 2008; 134: 711 (A-101).
69. Sumner, E.L., Slaughter, J.C., Farrokhi, F., Vaezi, M.F. Feasibility of proximal esophageal wireless capsule placement: blinded sham-controlled study. *Gastroenterology* 2008; 134: T2001 (A-597).
70. Smith, B.S., Slaughter, J.C., Ness, R.M., Vaezi, M.F. In refractory GERD patients should we perform impedance on therapy or pH monitoring off therapy? *Gastroenterology* 2008; 134: T2008 (A-599).
71. Vaezi, M.F., Hagaman, D.D., Slaughter, J.C., Tanner, B.S., Duncavage, J.A., Allocco, C., Sparkman, C.C., Clement, L., Wasden, C.M., Wirth, D.C., Goutte, M., McCafferty, B.A., Farrokhi, F. A Randomized Double-Blind Placebo-Controlled Study of Acid Suppression for Isolated Chronic Postnasal Drip. *Gastroenterology* 2009; 136: 685 (A-107)
72. Shepherd, B.D., Slaughter, J.C., Vaezi, M.F. Eosinophilic Esophagitis: Dilate or Medicate? *Gastroenterology*, *Gastroenterology* 2009; 136: S1869 (A-281-A-282)
73. Klochan, C.M., Slaughter, J.C., Trawick, E.P., Vaezi, M.F. Acid Reflux Parameters Have the Greatest Influence On the Total Number of Impedance Events in GERD. *Gastroenterology* 2009; 136: S1905 (A-289)

74. Trawick, E.P., Slaughter, J.C., Klochan, C.M., Vaezi, M.F. Impedance Monitoring in Refractory GERD: SI, SAP or Number of Events? *Gastroenterology* 2009; 136: 1896 (A-287)
75. Muddana, S., Slaughter, J.C., Garrett, C.G., Goutte, M., Vaezi, M.F. One Step Closer to Finding Out What Restech pH Is Telling Us: Normal vs GERD? *Gastroenterology* 2009; 136: S1893 (A-286)
76. Klochan, C.M., Slaughter, J.C., Trawick, E.P., Holzman, M., Vaezi, M.F. Fundoplication in Patients with Extraesophageal Reflux (EER) Refractory to PPI Therapy: Trust Clinical Judgment Over Impedance or pH. *Gastroenterology* 2009; 136: 687 (A-107)
77. Hong, S.K., Slaughter, J.C., Garrett, C.G., Pritchett, J.M., Vaezi, M.F. "Silent Reflux": Can It Happen? *Gastroenterology* 2009; 136: W1831 (A-734-A-735)
78. Hong, S.K., Dettmar, P.W., Slaughter, J.C., Strugala, V., Goutte, M., Vaezi, M.F. Salivary Pepsin in Patients with Refractory GERD: Double Blinded Assessment of Test Sensitivity, Specificity, Positive and Negative Predictive Values. *Gastroenterology* 2009; 136: 382 (A-63)
79. Shepherd, B.D., James Slaughter, J.C., Aznaurov, S, Barry, D., Vaezi, M.F. Silent GERD: Is It Different Physiologically than GERD? *Am J Gastroenterol* 2009; 104: S1-S40 (23)
80. Mukhtar, N., Ochieng', M., Goutte, M., Slaughter, J.C., Vaezi, M.F. The New Restech Dx-pH Probe for GERD: *in Vitro* and *in Vivo* Validation. *Am J Gastroenterol* 2009; 104: S1-S40 (43)
81. Schneider, J., Yasar Ishaq, Y., Slaughter, J.C., Goutte, M., Vaezi, M.F. SI & SAP: Useful or Inflated Importance? *Am J Gastroenterol* 2009; 104: S1-S40 (53)
82. Aslam, M., Goutte, M., Slaughter, J.C., Garrett, C.G., Vaezi, M.F. BMI and Esophageal Acid Exposure in Extraesophageal GERD: A Non-Linear Relationship. *Gastroenterology* 2010; 138 : W1056 (S-641-S-642)
83. Moore, J.M., Goutte, M., Slaughter, J.C., Garrett, C.G., Vaezi, M.F. Esophageal Acid Exposure Profile in Patients With Extraesophageal Symptoms: Not What You Expect From History Taking Alone. *Gastroenterology* 2010; 138 : W1069 (S-644-S-645)

84. Goutte, M., Jerome, W.G., Washington, K., Slaughter, J.C., Garrett, C.G., Vaezi, M.F. Esophageal and Laryngeal Dilated Intracellular Space in GERD and Chronic Laryngitis: A Prospective Blinded Assessment. *Gastroenterology* 2010; 138 : 874 (S-121-S-122)
85. Oranu, A.C., Rymer, J.A., Goutte, M., Slaughter, J.C., Garrett, C.G., Vaezi, M.F. SI & SAP Not as Useful in Extra-Esophageal Reflux. *Gastroenterology* 2010; 138: 878 (S-122-S-123)
86. Slaughter, J.C., Goutte, M., Vaezi, M.F. Neither SI or SAP are Reliable Tools for Assessing Symptoms and Reflux Events. *Gastroenterology* 2010; 138: T1097 (S-487).
87. Vaezi MF, Hagaman DD, Slaughter JC, Tanner SB, et al. Proton pump inhibitor therapy improves symptoms in post nasal drainage. *Gastroenterology* 2010; 139: Supplement.
88. Stamler D, Fass R, Vaezi MF, Sharma P, Bian A, Valentine K, Huff J. Clinical characteristics of GERD patients who incompletely responded to PPI therapy. *Gastroenterology* 2011; 140: A420.
89. Goutte M, Slaughter JC, Garrett CG, Hagaman DD, Tanner SB, Vaezi MF. What does impedance monitoring on PPI therapy tell us? *Gastroenterology* 2011; 140: S43.
90. Castell DO, Zerbib F, des Varannes SB, Galmiche JP, Vaezi MF, Keywood C. Efficacy and tolerability of ADX10059 a mGluR5 negative allosteric modulator as add on therapy to proton pump inhibitors in patients with GERD. *Gastroenterology* 2011; 140:S577.
91. Rymer JA, Francis DO, Goutte M, Slaughter JC, Garrett CG, Hagaman DD, Tanner SB, Vaezi MF. Economic burden of extraesophageal reflux disease. *Gastroenterology* 2011; 140: S136-37.
92. Vaezi MF, Mabary J, Higginbotham T, Yuksel ES, Slaughter JC. A novel device measuring esophageal mucosal consequences of chronic GERD. *Gastroenterology* 2012; 142:S-167.
93. Vaezi MF, Higginbotham T, Kavitt RT, Patel D, Lominadz Z, Abou-Ismael A, Pasricha T, Yuksel ES, Slaughter JC. Do patients report symptoms when they occur? Fundamental consequences for interpretation of ambulatory reflux monitoring. *Gastroenterology* 2012; 142:S415.
94. Vaezi MF. Effects, diagnosis and management of extraesophageal reflux. *Gastroenterology* 2012; 143: 866-67.
95. Kavitt RT, Penson DF, Vaezi MF. Dilate or medicate? Decision analysis of initial treatment strategies in eosinophilic esophagitis. *Gastroenterology* 2012; 142: S434.
96. Kavitt RT, Yuksel ES, Slaughter JC, Garrett CG, Higginbotham T, Vaezi MF. Clinical implications of impedance monitoring in suspected extraesophageal reflux: can the

- traditional physiologic parameters predict impedance results? *Gastroenterology* 2012; 142: S101.
97. Yuksel ES, Slaughter JC, Kavitt RT, Garrett CG, Higginbotham T, Vaezi MF. Demographic and physiologic distinction among extraesophageal reflux syndromes: they are not all the same. *Gastroenterology* 2012; 142: S411.
  98. Kavitt RT, Slaughter JC, Garrett G, Vaezi MF. Predictor of response in patients with chronic cough and GERD. *Gastroenterology* 2013; 144:S51.
  99. Yuksel ES, Slaughter JC, Higginbotham T, Mabary JE, Vaezi MF. Esophageal mucosal impedance. *Gastroenterology* 2013; 144:S118-119.
  100. Aberra F, Ates F, Li Z, Slaughter JC, Higginbotham T, Vaezi MF. Appropriateness of upper endoscopy referrals in patients with GERD by specialty. *Gastroenterology* 2014; 146:S749-750
  101. Ates F, Higginbotham T, Slaughter JC, Mabary J, Vaezi MF. Esophageal mucosal impedance pattern in GERD and non-GERD. *Gastroenterology* 2014; 146:S117.
  102. Kavitt RT, Ates F, Slaughter JC, Higginbotham T, Vaezi MF. Dilate or medicate? A randomized controlled trial comparing esophageal dilation to no dilation among patients with EoE. *Gastroenterology* 2014; 146:S16-17.
  103. Patel DA, Ates F, Slaughter JC, Higginbotham T, Vaezi MF. Esophageal acid exposure consistency as a measure of pH reliability. *Gastroenterology* 2014; 146:S751-52.
  104. Vaezi MF, Vakil NB, Schmalz MJ, Raymond A. Multicenter prospective study of the upper esophageal sphincter assist device for the treatment of EER. *Gastroenterology* 2014; 146:S128.
  105. Vaezi MF, Fass R, Reasner D, Hall M, Olson T, Currie MG, Lavins BJ. IW-3718, a novel gastric retentive bile acid swellant improved symptoms of refractory GERD in a double blind placebo controlled phase 2a study. *Am J Gastroenterol* 2015, 110: A1661
  106. Silvers ST, Vaezi MF, Vakil NB, Schmalz J, Raymond A, Miller JS, Maris NJ. Comparison of two studies of UES assist device. *Gastroenterology* 2015; 148:S607.
  107. Patel D, Slaughter JC, Patel A, Patel A, Higginbotham T, Ates F, Gyawali P, Vaezi MF. GERD: can we predict who will develop esophagitis? *Gastroenterology* 2015; 148:S613.
  108. Zifodya JS, Kim HP, Silver H, Slaughter JC, Higginbotham T, Vaezi MF. Nutritional status of patients with untreated achalasia. *Gastroenterology* 2015; 148:S819-20

109. Kim HP, Heller LT, Ates F, Yuksel ES, Slaughter JC, Higginbotham T, Vaezi MF. Intraluminal impedance vs mucosal impedance testing for the diagnosis of GERD: do they measure the same thing? *Gastroenterology* 2015; 148: S 615-6.
110. Kavitt R, Yuksel E, Ates F, Slaughter JC, Higginbotham T, Vaezi MF. Esophageal MI pattern in patients with extraesophageal GERD. *Gastroenterology* 2015; 148: S54.
111. Choksi YA, Sharda R, Slaughter JC, Higginbotham T, Vaezi MF. Critical evaluation of functional and hypersensitive esophageal symptoms diagnosed by pH monitoring: It's time to rethink what we recommend. *Gastroenterology* 2016; 150:S279.
112. Sharda R, Choksi YA, Higginbotham T, slaughter JC, Lal P, Yuksel ES, Ates F, Vaezi MF. Reducing mucosal impedance variability by ensuring direct contact with esophageal mucosa. *Gastroenterology* 2016; 150:S272.
113. Krill JT, Naik RD, Higginbotham T, Slaughter JC, Holzman MD, Vaezi MF. The predictors of response to antireflux surgery in extraesophageal reflux. *Gastroenterology* 2016; 150:S111.
114. Wright MR, Higginbotham T, Slaughter JC, Ates F, Yuksel ES, Vaezi MF. Mucosal impedance in Barrett's esophagus: can it assess compliance with medication? *Gastroenterology* 2016; 150:S260.
115. Higginbotham T, Lal P, Slaughter JC, Vaezi MF. Mucosal impedance measurement at index endoscopy can diagnose EoE without the need for histology. *Gastroenterology* 2016; 150:S136.
116. Choksi YA, Lal P, Slaughter JC, Higginbotham T, Ates F, Yuksel ES, Vaezi MF. Mucosal impedance differentiates esophageal disorders eliminating the need for ambulatory monitoring. *Gastroenterology* 2016; 150:S35-6.
117. Sharda R, Patel D, Hovis KL, Penson D, Feurer I, McPheeters M, Vaezi MF, Francis DO. Developmental characteristics of GERD and dysphagia-related patient reported outcome measures: a systematic review. *Gastroenterology* 2016; 150:S272-3.
118. Francis DO, Sharda R, Patel D, Hovis KL, Penson D, Feurer I, McPheeters M, Vaezi MF. Developmental characteristics of extraesophageal reflux-related patient reported outcome measures: a systematic review. *Gastroenterology* 2016; 150:S267-8.
119. Patel DA, Slaughter JC, Higginbotham T, Vaezi MF. Predicting abnormal ph in patients with HB: can we do it at bedside? *Gastroenterology* 2017; 152:S656.
120. Patel DA, Wright MR, Higginbotham T, Slaughter JC, Vaezi MF. Novel balloon MI for GERD and EoE. *Gastroenterology* 2017; 152:S43.



121. Patel DA, Naik RD, Slaughter JC, Higginbotham T, Silver HJ, Vaezi MF. Weight loss in achalasia is determined by its phenotype. *Gastroenterology* 2017; 152:S196.
122. Choksi YA, Shard R, Higginbotham T, Williams CS, Vaezi MF. Sublaryngeal esophageal tissue does not resemble mid to distal tissue in patients with active EoE. *Gastroenterology* 2017; 152:S28.
123. Hiremath GS, Vaezi MF, Gupta SK, Acra S, Dellon ES. Management of uncomplicated esophageal food impaction varies substantially between pediatric and adult gastroenterologists practicing in the US. *Gastroenterology* 2017; 152:S433-34.
124. Shard R, Choksi YA, Lal Pooja, Slaughter JC, Higginbotham T, Vaezi MF. Do all patients with suspected extraesophageal reflux need pH testing? *Gastroenterology* 2017; 152:S130-31.
125. Choksi YA, Katzka DA, Stengel K, Higginbotham T, Pierce K, Hiebert S, Vaezi MF, Williams CS. Topical steroid treatment modifies pathways associated with cell adhesion and EMT in EoE. *Gastroenterology* 2017; 152:S28-29.
126. Sarker S, Patel DA, Higginbotham T, Slaughter JC, Vaezi MF. Direct comparison of MI, MNBI, PSPW and impedance pH in patients with continued symptoms on therapy. *Gastroenterology* 2018; 154; S487.
127. Patel DA, Evers L, Slaughter JC, Higginbotham T, Vaezi MF, Adams DW. Duodenal mucosal impedance is altered in patients with Celiac Disease. *Gastroenterology* 2018; 154:S443-4.
128. Choksi YA, Blanco M, Sarker S, Aslam M, Higginbotham T, Vaezi MF. MI pattern differentiates esophageal inflammatory states. *Gastroenterology* 2018; 154:S254-5.
129. Naik RD, Patel DA, Lareu N, Higginbotham, Aslam M, Salaria S, Washington K, Schey K. Vaezi MF. Proteomic, lipidomic and histological identification of Ex-vivo achalasia esophageal samples to assess the immune mediated response and neuronal degeneration process. *Gastroenterology* 2018; 154:S731.
130. Choksi YA, Short SP, Keating C, Thompson JJ, Katzka DA, Vaezi MF, Williams CS. Gpx3 is reduced in EoE patients and regulates esophageal epithelia homeostasis in a 3D organoid model. *Gastroenterology* 2018; 154:S262.
131. Alexander JA, Ravi K, Geno DM, Tholen C, Higginbotham, T, Wildhorn S, Vaezi MF, Katzka DA. Biopsy alone does not reliably assess disease activity and heterogeneity measured by esophageal balloon MI in patients with EoE. *Gastroenterology* 2018; 154:S244-5.

132. Patel DA, Bennett A, Sarker S, Higginbotham T, Slaughter JC, Aslam M, Vaezi MF. Concordance between MI and index endoscopy wireless Ph monitoring: a prospective blinded study. *Gastroenterology* 2018; 154:S481-2.
133. Lei W, Chen CL, Chang WC, et al. Application of novel MI in patients with GERD. *Gastroenterology* 2018; 154:S478-9.
134. Vaezi MF, Fass R, Vakil N, Mittleman R, Hall M, et al. Iw-3718 a novel gastric retentive bile acid sequestrant improved heartburn and regurgitation symptoms in patients with persistent GERD despite PPI treatment.: A double blind placebo controlled study. *Gastroenterology* 2018; 154:S174.
135. Barrett C, Patel D, Ferguson S, Higginbotham T, Slaughter J, and Vaezi M. Esophageal mucosal integrity is unchanged in patients with functional heartburn and reflux hypersensitivity (2019). Abstract/Poster presentation. Digestive Disease Week (DDW), San Diego, CA.
136. Patel D, Goss J, Tombazzi C, Higginbotham T, Slaughter J, and Vaezi M. Impact of chronic opiates on esophageal physiology: An observational cohort study (2019). Abstract/Poster presentation. Digestive Disease Week (DDW), San Diego, CA.
137. Ajayi T, Blanco M, Patel D, Barrett C, Ferguson S, Higginbotham T, Slaughter J, and Vaezi M. BMI rather than symptoms is associated with altered esophageal mucosal integrity in patients with refractory GERD (2019). Oral Presentation. Digestive Disease Week (DDW), San Diego, CA.
138. Izmaylov M, Sarker S, Patel D, Choksi Y, Higginbotham T, Slaughter J, and Vaezi M. Esophageal pathology is the likely etiology dysphagia regardless of cervical or substernal localization (2019). Abstract/Poster presentation. Digestive Disease Week (DDW), San Diego, CA.
139. Naik R, Barrett C, Ferguson S, Slaughter J, Higginbotham T, Patel D, and Vaezi M. Mucosal integrity testing can detect changes in esophageal and extraesophageal GERD (2019). Oral Presentation. Digestive Disease Week (DDW), San Diego, CA.
140. Hayat M, Naik R, Vaezi M, and Patel D. Assessment of emergency department visits, hospital admission trends, and financial burden of eosinophilic esophagitis: A national inpatient sample database study (2020). Abstract/Poster Presentation. American College of Gastroenterology (ACG), Nashville, TN.
141. Meyers M, Hayat M, Tombazzi C, Slaughter J, Higginbotham T, Patel D, Vaezi M, and Naik R. Pre-transplant GERD does not predict post-lung transplant mortality, acute rejection, or chronic rejection: a 10 year retrospective review (2020). Abstract/Poster Presentation. American College of Gastroenterology (ACG), Nashville, TN.

142. Patel D, Goss J, Tombazzi C, Hayat M, Higginbotham T, Slaughter J, Naik R, and Vaezi M. Partial opioid agonist are not associated with opioid induced esophageal dysfunction (2020). Abstract/Poster Presentation. Digestive Disease Week (DDW), Chicago, IL.
143. Patel D, Higginbotham T, Slaughter J, Wildhorn S, and Vaezi M. Mucosal integrity testing or pH monitoring: Time to re-evaluate the gold standard? (2020). Abstract/Poster Presentation. Digestive Disease Week (DDW), Chicago, IL.
144. Meyers M, Patel D, Higginbotham T, Slaughter J, Wildhorn S, and Vaezi M. Mucosal integrity testing can rule out reflux in refractory GERD (2020). Abstract/Poster Presentation. Digestive Disease Week (DDW), Chicago, IL.
145. Patel D, Higginbotham T, Slaughter J, Wildhorn S, and Vaezi M. Mucosal integrity testing: Primed to bring personalized medicine to gastroenterology (2020). Abstract/Poster Presentation. Digestive Disease Week (DDW), Chicago, IL.
146. Ajayi T, Shah K, Yazdian A, Naik R, Higginbotham T, Slaughter J, Vaezi M, and Patel D. Achalasia phenotype is associated with predictable post-myotomy weight changes regardless of esophageal diameter (2020). Abstract/Poster Presentation. Digestive Disease Week (DDW), Chicago, IL.
147. Lal P, Patel D, Naik R, Carlson D, Pandolfino J, Mashi M, Gyawali C, Higginbotham T, Slaughter J, and Vaezi M. Mucosal integrity testing has high concordance for gastroesophageal reflux disease: A multicenter prospective cohort study (2021). Oral presentation. Digestive Disease Week.
148. Hayat M, Naik R, Vaezi M, and Patel D. Hospital admission characteristics and treatment cost of achalasia: A time-trend analysis of the last two decades in United States. (2021). Abstract/Poster of Distinction. Digestive Disease Week.
149. Oje A, Hayat M, Naik R, Higginbotham T, Slaughter J, Vaezi M, and Patel D. Opioid dose and patient age predict abnormal manometric diagnosis in patients on opioids (2021). Abstract/Poster Presentation. Digestive Disease Week.
150. Shah K, Hayat M, Naik R, Higginbotham T, Slaughter J, Vaezi M, and Patel D. Opioid exposure is associated with spastic disorders in patients with dysphagia. (2021). Abstract/Poster Presentation. Digestive Disease Week.
151. Meyers M, Hayat M, Oje A, Tombazzi C, Slaughter J, Higginbotham T, Patel D, Vaezi M, and Naik R. Pre-Transplant GERD predicts acute rejection in lung transplant: A 10-year retrospective review. (2021). Abstract/Poster of Distinction. Digestive Disease Week.

